<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease - Gjuladin‐Hellon, T - 2019 | Cochrane Library</title> <meta content="Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease - Gjuladin‐Hellon, T - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008414.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease - Gjuladin‐Hellon, T - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008414.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008414.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease" name="citation_title"/> <meta content="Teuta Gjuladin‐Hellon" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Morris Gordon" name="citation_author"/> <meta content="Zipporah Iheozor‐Ejiofor" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Anthony K Akobeng" name="citation_author"/> <meta content="Sidra Medicine" name="citation_author_institution"/> <meta content="aakobeng@sidra.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD008414.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/06/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008414.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008414.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008414.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; *Crohn Disease [drug therapy, surgery]; *Mesalamine [therapeutic use]; Administration, Oral; Quality of Life; Randomized Controlled Trials as Topic; Recurrence" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008414.pub3&amp;doi=10.1002/14651858.CD008414.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008414\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008414\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","zh_HANS","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008414.pub3",title:"Oral 5\\u2010aminosalicylic acid for maintenance of surgically\\u2010induced remission in Crohn\u0027s disease",firstPublishedDate:"Jun 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008414.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008414.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008414.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008414.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008414.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008414.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008414.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008414.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008414.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008414.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2783 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008414.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/appendices#CD008414-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/table_n/CD008414StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/table_n/CD008414StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information#CD008414-cr-0002">Teuta Gjuladin‐Hellon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information#CD008414-cr-0003">Morris Gordon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information#CD008414-cr-0004">Zipporah Iheozor‐Ejiofor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information#CD008414-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Anthony K Akobeng</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information/en#CD008414-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 June 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008414.pub3">https://doi.org/10.1002/14651858.CD008414.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008414-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008414-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008414-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008414-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008414-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008414-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008414-abs-0001" lang="en"> <section id="CD008414-sec-0001"> <h3 class="title" id="CD008414-sec-0001">Background</h3> <p>Crohn’s disease (CD) is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. 5‐Aminosalicylates (5‐ASAs) are locally acting, anti‐inflammatory compounds that reduce inflammation of the colonic mucosa with release profiles that vary among various commercially available formulations. This updated Cochrane review summarizes current evidence on the use of 5‐ASA formulations for maintenance of surgically‐induced remission in CD. </p> </section> <section id="CD008414-sec-0002"> <h3 class="title" id="CD008414-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of 5‐ASA agents for the maintenance of surgically‐induced remission in CD. </p> </section> <section id="CD008414-sec-0003"> <h3 class="title" id="CD008414-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register from inception to 16 July 2018. We also searched references, conference abstracts, and trials registers. </p> </section> <section id="CD008414-sec-0004"> <h3 class="title" id="CD008414-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that included participants with CD in remission following surgery and compared 5‐ASAs to no treatment, placebo or any other active intervention with duration of at least three months were considered for inclusion. </p> </section> <section id="CD008414-sec-0005"> <h3 class="title" id="CD008414-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. The primary outcome was clinical relapse. Secondary outcomes included endoscopic recurrence, radiologic and surgical relapse, adverse events, serious adverse events and withdrawal due to adverse events. </p> </section> <section id="CD008414-sec-0006"> <h3 class="title" id="CD008414-sec-0006">Main results</h3> <p>Fourteen RCTs (1867 participants) were included in the review. Participants (15 to 70 years) were recruited from gastroenterology hospitals and medical clinics in Europe and North America and followed up between 3 and 72 months. The risk of bias was assessed as 'low' in one study, 'unclear' in seven and as 'high' in six. </p> <p>At 12 months, 36% (20/55) of participants in the 5‐ASA group experienced clinical relapse compared to 51% (28/55) in the no treatment control group (RR 0.71, 95% CI 0.46 to 1.10; low certainty evidence). Moderate certainty evidence suggests that 5‐ASAs are more effective for preventing clinical relapse than placebo. During a follow‐up period of 12 to 72 months, 36% (131/361) of 5‐ASA participants relapsed compared to 43% (160/369) of placebo participants (RR 0.83, 95% CI 0.72 to 0.96; I² = 0%; moderate certainty evidence). At 12 months, 17% (17/101) of the 4 g/day mesalamine group relapsed compared to 26% (27/105) of the 2.4 g/day group (RR 0.65, 95% CI 0.38 to 1.13; moderate certainty evidence). There was no evidence of a difference in clinical relapse rates when 5‐ASA compounds were compared to purine antimetabolites. At 24 months, 61% (103/170) of mesalamine participants relapsed compared to 67% (119/177) of azathioprine participants (RR 0.90, 95% CI 0.76 to 1.07; I² = 28%; low certainty evidence). During 24 months, 50% (9/18) of 5‐ASA participants had clinical relapse compared to 13% (2/16) of adalimumab participants (RR 4.0, 95% CI 1.01 to 15.84; low certainty evidence). The effects of sulphasalazine compared to placebo on clinical relapse rate is uncertain. After 18 to 36 months, 66% (95/143) of participants treated with sulphasalazine relapsed compared to 71% (110/155) in the placebo group (RR 0.88, 95% CI 0.56 to 1.38; I² = 38%; low certainty evidence). </p> <p>The effect of 5‐ASA drugs on safety was uncertain. During 24 months follow‐up, 4% (2/55) of 5‐ASA participants experienced adverse events compared to none (0/55) in the no treatment control group (RR 5.00, 95% CI 0.25 to 101.81; very low certainty evidence). An equal proportion of 5‐ASA participants (10%; 23/241) and placebo (9%; 20/225) groups experienced an adverse event during a follow‐up of 3 to 72 months (RR 1.07, 95% CI 0.60 to 1.91; I² = 0%; low certainty evidence). Adverse event rates were similar in the 5‐ASA and purine analogues groups. However, serious adverse events and withdrawals due to adverse events were more common in participants who received purine analogues than 5‐ASA. At 52 weeks to 24 months, 52% (107/207) of 5‐ASA participants had an adverse event compared to 47% (102/218) of purine analogue participants (RR 1.11, 95% CI 0.97 to 1.27, I² = 0%; low certainty evidence). Four per cent (6/152) of 5‐ASA participants had a serious adverse event compared to 17% (27/159) of purine analogue participants (RR 0.30, 95% CI 0.11 to 0.80; very low certainty evidence). Eight per cent (17/207) of 5‐ASA participants withdrew due to an adverse event compared to 19% (42/218) of purine analogue participants (RR 0.48, 95% CI 0.28 to 0.83; low certainty evidence). Adverse event rates were similar in high and low dose mesalamine participants. After 12 months, 2% (2/101) of 4 g/day mesalamine participants had an adverse event compared to 2% (2/105) of 2.4 g/day participants (RR 1.04, 95% CI 0.15 to 7.24; low certainty evidence). The proportion of participants who experienced adverse events over a 24 month follow‐up in the mesalamine group was 78% (14/18) compared to 69% (11/16) of adalimumab participants (RR 1.13, 95% CI 0.75 to 1.71; very low certainty evidence). None (0/32) of the sulphasalazine participants had an adverse event at 18 months follow‐up compared to 3% (1/34) of the placebo group (RR 0.35, 95% CI 0.01 to 8.38; very low certainty evidence). Commonly reported adverse events in the included studies were diarrhoea, nausea, increased liver function tests, pancreatitis, and abdominal pain. </p> </section> <section id="CD008414-sec-0007"> <h3 class="title" id="CD008414-sec-0007">Authors' conclusions</h3> <p>5‐ASA preparations are superior to placebo for the maintenance of surgically‐induced clinical remission in patients with CD (moderate certainty). The number needed to treat to prevent one relapse was 13 patients. The evidence for endoscopic remission is uncertain. The sulphasalazine class of 5‐ASA agents failed to demonstrate superiority against placebo, 5‐ASAs failed to demonstrate superiority compared to no treatment (very low and low certainty). The efficacy of two different doses of the same 5‐ASA and the efficacy of 5‐ASA compared to purine antimetabolites (azathioprine or 6‐mercaptopurine) in maintaining surgically‐induced remission of CD remains unclear. However, purine analogues lead to more serious adverse events and discontinuation due to adverse events. There is a low certainty that 5‐ASA is inferior for maintaining surgically‐induced remission of CD compared to biologics (anti TNF‐ɑ). 5‐ASA formulations appear to be safe with no difference in the occurrence of adverse events or withdrawal when compared with placebo, no treatment or biologics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008414-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008414-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008414-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008414-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008414-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008414-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008414-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008414-abs-0004" lang="en"> <h3>Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn’s disease </h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this review was to understand the effectiveness and safety of 5‐ASA drugs for maintaining remission following surgery in people with Crohn disease. This review is an update of a previously published Cochrane review. </p> <p><b>What is Crohn's disease?</b> </p> <p>Crohn's is a chronic disease of the gut. Crohn's changes from periods when sufferers have symptoms (relapse) to periods when the symptoms disappear (remission). Symptoms include abdominal pain, diarrhoea and weight loss. People with Crohn's disease may undergo surgery to remove diseased parts of their gut. However, their symptoms may return after a short time. Different drugs can be given to maintain remission, however, there are concerns about possible side effects. 5‐ASA drugs reduce inflammation (pain and swelling) in the gut. We researched whether 5‐ASA can maintain remission in people with Crohn's after the diseased part of their gut has been removed. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to 16 July 2018.</p> <p><b>What are the main results of the review?</b> </p> <p>We found 14 studies (1867 participants). One study was judged to be of high quality, six studies were of low quality and seven were judged to be unclear as authors reported insufficient information to allow a judgement. People who took 5‐ASA had fewer relapses than people who had no maintenance treatment. At 12 months, 36% (20/55) of participants in the 5‐ASA group relapsed compared to 51% (28/55) in the no treatment control group (1 study, low certainty evidence). Moderate quality evidence from five studies showed that 5‐ASA drugs are superior to placebo (e.g. a sugar pill) for maintaining surgically‐induced remission of Crohn's disease. During a follow‐up period of 12 to 72 months, 36% (131/361) of 5‐ASA participants relapsed compared to 43% (160/369) of placebo participants. The analysis of four studies that compared 5‐ASA medications to purine antimetabolites (i.e. azathioprine or 6‐mercaptopurine ‐ both immunosuppressive drugs) found no difference in the proportion of participants that remained in remission, although the overall quality of evidence was low. At 24 months, 61% (103/170) of 5‐ASA participants relapsed compared to 67% (119/177) of purine antimetabolite participants. People who took high dose 5‐ASA had fewer relapses than those who took lower dose 5‐ASA. At 12 months, 17% (17/101) of the 4 g/day 5‐ASA group relapsed compared to 26% (27/105) of the 2.4 g/day group (1 study, moderate certainty evidence). The analysis of the single small study that compared 5‐ASA and adalimumab (a biologic drug) showed that 5‐ASA was inferior to adalimumab for maintaining surgically‐induced remission of Crohn's disease. At 24 months, 50% (9/18) of 5‐ASA participants relapsed compared to 13% (2/16) in the adalimumab group (very low certainty evidence). The analysis of two studies that compared sulphasalazine to placebo found no difference in relapse rates. After 18 to 36 months, 66% (95/143) of sulphasalazine participants relapsed compared to 71% (110/155) of placebo participants (low certainty evidence). There was no difference in rates of side effects, serious side effects and withdrawal due to side effects when 5‐ASA was compared to placebo. 5‐ASA was safer than purine analogues resulting in less serious side effects and discontinuation of treatment due to side effects. Commonly reported side effects included diarrhoea, nausea, increased liver function tests, pancreatitis and abdominal pain. </p> <p><b>Conclusions</b> </p> <p>5‐ASA drugs are superior to placebo for maintaining surgically‐induced remission of Crohn's disease (moderate certainty evidence). Sulphasalazine failed to demonstrate superiority against placebo (very low certainty evidence), and similarly 5‐ASAs failed to demonstrate superiority to no treatment (low certainty evidence). The effectiveness of two different doses of the same 5‐ASA and the effectiveness of 5‐ASA compared to purine antimetabolites (azathioprine or 6‐mercaptopurine) for maintaining surgically‐induced remission of Crohn's disease remains unclear. However, purine analogues lead to more serious side effects and discontinuation due to side effects than 5‐ASA. There is a low certainty that 5‐ASA is inferior to adalimumab for maintaining surgically‐induced remission of CD. There was no evidence of a difference in the occurrence of side effects or withdrawal due to side effects with 5‐ASA formulations when compared with placebo, no treatment or biologics. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008414-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008414-sec-0087">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008414-sec-0142">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008414-sec-0087"></div> <h3 class="title" id="CD008414-sec-0088">Implications for practice</h3> <section id="CD008414-sec-0088"> <p>Moderate certainty evidence suggests that 5‐ASA preparations are superior to placebo for the maintenance of surgically‐induced clinical remission in patients with Crohn’s disease. The number needed to treat to prevent one relapse was 13 patients. However, the effect of 5‐ASA on endoscopic remission was uncertain. These findings require careful consideration given that endoscopic recurrence has been shown to precede clinical relapse. There was no evidence of a difference in the rate of adverse events, serious adverse events or withdrawals in the 5‐ASA or placebo groups, but this was rated as low certainty evidence. The analysis of the studies comparing sulphasalazine to placebo did not demonstrate superiority, but this result was of low or very low certainty due to sparse data and risk of bias. This was also the case for the one study that compared 5‐ASA with no treatment. There was no difference between 5‐ASA (mesalamine) and purine analogues (azathioprine) in efficacy, but there was evidence of lower rates of serious adverse events and withdrawals due to adverse events with 5‐ASA agents. However, the evidence was rated as low or very low certainty. Finally, in one study 5‐ASA was inferior to anti TNF‐ɑ agents, although the evidence was rated as very low certainty. </p> </section> <h3 class="title" id="CD008414-sec-0089">Implications for research</h3> <section id="CD008414-sec-0089"> <p>Further studies investigating the efficacy of 5‐ASA for maintenance of endoscopic remission may be required. However, given that the current international guidance recommends post‐surgical prophylaxis over no intervention (<a href="./references#CD008414-bbs2-0045" title="NguyenGC , LoftusEVJr , HiranoI , Falck‐YtterY , SinghS , SultanS , et al. American gastroenterological association institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology2017;152(1):271‐5. ">Nguyen 2017</a>), it is proposed that further studies would be best placed to investigate both endoscopic and clinical outcomes for 5‐ASA when compared with purine analogues and anti TNF‐ɑ. Key to these studies is the need to address both design and reporting issues that have been identified in both versions of this review, as well as enrolling enough participants to allow for adequate statistical power. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008414-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008414-sec-0022"></div> <div class="table" id="CD008414-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">5‐ASA compared to no treatment for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASA compared to no treatment for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> 5‐ASA (2.4 g/day)<br/> <b>Comparison:</b> no Treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>509 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>361 per 1,000<br/> (234 to 560) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.71<br/> (0.46 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110<br/> (1 Study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients in whom CDAI was &gt; 150, and who presented 100 points over their previous value, were considered to be relapsed (<a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.00<br/> (0.25 to 101.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 Study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to calculate absolute effects. Adverse events occurred in 4% (2/55) of participants in the 5‐ASA group compared to 0% (3/55) in the no treatment control group </p> <p>Reported adverse events included skin rash, epigastric pain, vomiting and nausea</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1,000<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 5.00<br/> (0.25 to 101.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> <p>( 1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We were unable to calculate absolute effects. Adverse events occurred in 4% (2/55) of participants in the 5‐ASA group compared to 0% (3/55) in the no treatment control group </p> <p>Withdrawals due to adverse events included skin rash, epigastric pain, vomiting and nausea </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of performance bias and unclear risk of selection of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (48 events) </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision (2 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008414-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">5‐ASAs compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASAs compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> 5‐ASA (3 to 4 g/day)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 48 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>360 per 1,000<br/> (312 to 416) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.72 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse defined as CDAI &gt;150 (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>); CDAI ≥ 250 (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>); clinical recurrence score &gt; 2 (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>); severe symptoms that warrant treatment plus radiological/endoscopic evidence (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up:12 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>726 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>603 per 1,000<br/> (407 to 901) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.56 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enodscopic recurrence defined as Rutgeerts score i ≥1 (<a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>), Rutgeerts score i ≥ 2 (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>), Rutgeerrts score i <i>&gt; 2</i> (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up:12 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1,000<br/> (53 to 170) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.60 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events included skin lesions, abdominal pain, diarrhea , vomiting and nausea </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up:48 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (14 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06<br/> (0.44 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>577<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported serious adverse events included postoperative bowel obstruction and pancreatitis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:12 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1,000<br/> (49 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50<br/> (0.71 to 3.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included abdominal pain, pancreatitis and declining creatine clearance </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision (291 events)<br/> <sup>2</sup> Downgraded one level due to high risk of reporting bias and unclear risk of selection bias and outcome assessment<br/> <sup>3</sup> Downgraded two levels due to substantial heterogeneity ( I² = 84%)<br/> <sup>4</sup> Downgraded two levels due to very serious imprecision (43 events)<br/> <sup>5</sup> Downgraded two levels dur to due to very serious imprecision (18 events)<br/> <sup>6</sup> Downgraded two levels due to very serious imprecision (26 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008414-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High dose 5‐ASA compared to low dose 5‐ASA for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High compared to low dose 5‐ASAs for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention: high dose</b> 5‐ASAs (4.0 g/day)<br/> <b>Comparison: low dose</b> 5‐ASAs (2.4 g/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low dose 5‐ASA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with high dose 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1,000<br/> (98 to 291) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.38 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse reported as CDAI &gt; 150 or increase of 100 points from baseline (<a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>562 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1,000<br/> (337 to 584) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79<br/> (0.60 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic recurrence reported as Rutgeer's score &gt;1 (<a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000<br/> (3 to 138) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.15 to 7.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events include severe dyspepsia, increase in transaminases and limb cramps </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1,000<br/> (3 to 138) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04<br/> (0.15 to 7.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported adverse events include severe dyspepsia, increase in transaminases and limb cramps </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision (44 events) </p> <p><sup>2</sup> Downgraded one level due to due to serious imprecision (104 events) </p> <p><sup>3</sup> Downgraded two levels due to due to very serious imprecision (4 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008414-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">5‐ASA compared to purine antimetabolites for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASA compared to purine antimetabolites for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> 5‐ASA (3‐4 g/day)<br/> <b>Comparison:</b> purine antimetabolites </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with purine antimetabolites</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up:24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>672 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1,000<br/> (511 to 719) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.76 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse defined as a clinical grading score ≥ 2 (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>;<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) CDAI ≥ 200 (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>) </p> <p>CDAI &gt; 200 plus a 100‐point increase in CDAI from baseline (<a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up:24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>647 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>835 per 1,000<br/> (556 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (0.86 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic recurrence defined as Rugeerts score ≥ 2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up:24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>765 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>834 per 1,000<br/> (596 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.78 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiologic relapse defined as a radiographic grading score ≥ 2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up:52 weeks‐24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>468 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519 per 1,000<br/> (454 to 594) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11<br/> (0.97 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events included leukopenia, abdominal pain, nausea, nasopharyngitis, diarrhoea.and headache </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up:52 weeks to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1,000<br/> (19 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30<br/> (0.11 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>311<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported serious adverse events included postoperative bowel obstruction and pancreatitis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:52 weeks to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (54 to 160) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.48<br/> (0.28 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included severe epigastric intolerance, increase in liver function test results, leukopenia, acute pancreatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1118 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1,000</p> <p>(32 to 878)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.42</p> <p>(0.27 to 7.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝ <sup>1 8</sup><br/> VERY LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health related quality of life defined as IBDQ score &gt; 170</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to to high risk of performance bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (222 events) </p> <p><sup>3</sup> Downgraded two levels due to serious imprecision (26 events) </p> <p><sup>4</sup> Downgraded two levels due to serious imprecision (28 events) </p> <p><sup>5</sup> Downgraded one level due to serious imprecision (209 events) </p> <p><sup>6</sup> Downgraded two levels due to very serious imprecision (33 events) </p> <p><sup>7</sup> Downgraded one level due to serious imprecision (59 events) </p> <p><sup>8</sup> Downgraded two levels due to very serious imprecision (5 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008414-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">5‐ASAs compared to anti TNF‐ɑ for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASAs compared to anti TNF‐ɑ for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> 5‐ASAs (3 g/day)<br/> <b>Comparison:</b> anti TNF‐ɑ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti TNF‐ɑ</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1,000<br/> (126 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.00<br/> (1.01 to 15.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse defined as a grading score ≥ 2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000<br/> (124 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 13.33<br/> (1.98 to 89.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic recurrence defined as a Rutgeert's score ≥2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000<br/> (124 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 13.33<br/> (1.98 to 89.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiologic relapse defined as a score ≥2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1,000<br/> (516 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.13<br/> (0.75 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events included bronchitis, nasopharyngitis, abdominal pain, arthralgia and exacerbation of Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000<br/> (0 to 428) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30<br/> (0.01 to 6.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included atopic dermatitis and severe exacerbation of Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>875 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>166 per 1,000</p> <p>(61 to 473)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.19</p> <p>(0.07 to 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health related quality of life defined as (IBDQ &gt;170)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of performance bias and unclear risk of outcome assessment bias </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision (10 events) </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision (16 events) </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (25 events) </p> <p><sup>5</sup> Downgraded two levels due to very serious imprecision (1 event) </p> <p><sup>6</sup> Downgraded two levels due to very serious imprecision( 17 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008414-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sulphasalazine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sulphasalazine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> Sulphasalazine (3 g/day)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Sulphasalazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b><br/> Follow‐up:18 to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>710 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1,000<br/> (397 to 979) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88<br/> (0.56 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse was proven by radiological, endoscopic, or operation findings (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>) </p> <p>Clinical relapse was measured by a scoring system that considered symptoms, signs and impact (<a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1,000<br/> (0 to 246) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.35<br/> (0.01 to 8.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Adverse events leading to withdrawal included nausea</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life (HRQL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for limitation due to high risk of reporting and detection bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (205 events) </p> <p><sup>3</sup> Downgraded one level due to unclear risk of bias for several domains </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (1 event) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008414-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008414-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008414-sec-0103">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD008414-sec-0023"></div> <section id="CD008414-sec-0024"> <h3 class="title" id="CD008414-sec-0024">Description of the condition</h3> <p>Crohn’s disease is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. There is no cure for the disease, so management strategies are instead focused on induction and maintenance of remission, as well as supporting the many other symptoms that impact patients affected by the condition. </p> <p>Approximately 75% of patients with Crohn’s disease will eventually undergo surgical resection and this can induce remission (<a href="./references#CD008414-bbs2-0029" title="BernellO , LapidusA , HellersG . Risk factors for surgery and postoperative recurrence in Crohn’s disease. Annals of Surgery2000;231:38‐45. ">Bernell 2000</a>). Recent studies suggest a rate of 3.8 operations per 100 person years (<a href="./references#CD008414-bbs2-0041" title="MaC , MoranGW , BenchimolEI , TargownikLE , HeitmanSJ , HubbardJH , et al. Surgical rates for Crohn’s disease are decreasing: A population‐based time trend analysis and validation study. American Journal of Gastroenterology2017;112:11840‐8. ">Ma 2017</a>). However, endoscopic recurrence of disease has been reported to be as high as 73% at one year post surgery (<a href="./references#CD008414-bbs2-0051" title="RutgeertsP , GeboesK , VantrappenG , BeylsJ , KerremansR , HieleM . Predictability of the postoperative course of Crohns disease. Gastroenterology1990;99(4):956‐63. ">Rutgeerts 1990</a>), and clinical relapse rates have been reported to range from 20% to 86% at five years post surgery <a href="./references#CD008414-bbs2-0052" title="RutgeertsP . Crohn's disease recurrence can be prevented after ileal resection. Gut2002;5:152‐3. ">Rutgeerts 2002</a>; <a href="./references#CD008414-bbs2-0035" title="GklavasA , DellaportasD , PapaconstantinouI . Risk factors for postoperative recurrence of Crohn’s disease with emphasis on surgical predictors. American Journal of Gastroenterology2017;30(6):598‐612. ">Gklavas 2017</a>). </p> <p>Given these high relapse rates, there have been many studies to identify potential methods of prolonging postoperative remission, but there is no standard therapy for the prevention of postoperative recurrence in Crohn’s disease (<a href="./references#CD008414-bbs2-0046" title="National Institute for Health and Care Excellence. Crohn's disease: management (clinical guideline). nice.org.uk/guidance/cg152 (accessed 1 October 2012). ">NICE 2012</a>). A number of agents have been studied, but considerable uncertainty remains as to the efficacy of such treatments. 5‐aminosalicylates are currently not recommended for maintenance of surgically‐induced endoscopic remission (<a href="./references#CD008414-bbs2-0045" title="NguyenGC , LoftusEVJr , HiranoI , Falck‐YtterY , SinghS , SultanS , et al. American gastroenterological association institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology2017;152(1):271‐5. ">Nguyen 2017</a>; <a href="./references#CD008414-bbs2-0047" title="National Institute for Health and Care Excellence. Crohn's disease: management (NICE guideline NG129). nice.org.uk/guidance/ng129 (accessed 3 May 2019). ">NICE 2019</a>). </p> </section> <section id="CD008414-sec-0025"> <h3 class="title" id="CD008414-sec-0025">Description of the intervention</h3> <p>5‐aminosalicylates are a group of compounds that have long been used in inflammatory bowel disease. The first 5‐aminosalicylate agent used in clinical practice was sulphasalazine. Sulphasalazine is composed of sulphapyridine linked by an azo bond to 5‐aminosalicylic acid (5‐ASA). Sulphasalazine was first used in the 1940s as a treatment for arthritis (<a href="./references#CD008414-bbs2-0058" title="Svartz N. SalazopyrinA . Salazopyrin, a new sulfanilamide preparation. Acta Medica Scandinavica1942;110:557‐90. ">Svartz 1942</a>). Improvement in gastrointestinal symptoms was noted in patients who had concurrent ulcerative colitis leading to further use of this agent in inflammatory bowel disease. </p> <p>When the oral dose of sulphasalazine reaches the colon, an azo‐reductase synthesised by colonic bacteria splits the azo‐bond yielding 5‐ASA and sulphapyridine. Literally all the sulphapyridine compound is being absorbed from the colon, while most of 5‐ASA remains in the colon and is excreted in the faeces. The role of sulphapyridine as a carrier molecule is to deliver 5‐ASA, the active therapeutic moiety of sulphasalazine, to the colon (<a href="./references#CD008414-bbs2-0028" title="Azad KhanAK , PirisJ , TrueloveSC . An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet1977;2(8044):892‐5. ">Azad Khan 1977</a>; <a href="./references#CD008414-bbs2-0039" title="KlotzU , MaierK , FischerC , HeinkelKT . Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New England Journal of Medicine1980;303(26):1499‐502. ">Klotz 1980</a>; <a href="./references#CD008414-bbs2-0060" title="HeesPA , BakkerJH , TongerenJH . Effect of sulphapyridine, 5‐aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut1980;21(7):632‐5. ">van Hees 1980</a>). However, the most severe adverse effects of sulphasalazine are caused by sulphapyridine (<a href="./references#CD008414-bbs2-0053" title="SchroderH , EvansDA . Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut1972;13(4):278‐84. ">Schroder 1972</a>). Sulphapyridine undergoes acetylation in the liver with subsequent excretion in the urine. Slow acetylator show more of the adverse effects of this component secondary to accumulation of sulphapyridine in the blood prior to excretion in the kidneys (<a href="./references#CD008414-bbs2-0032" title="DasKM , EastwoodMA , McManusJP , SircusW . Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. New England Journal of Medicine1973;289(10):491–5. ">Das 1973</a>). A number of investigations of the use of 5‐ASA as a single agent for the treatment of inflammatory bowel disease have recognised that 5‐ASA is indeed the active ingredient of sulphasalazine and that sulphapyridine is responsible for most of the side effects. 5‐ASA in its unprotected form is, however, readily absorbed in the proximal small intestine (<a href="./references#CD008414-bbs2-0044" title="MyersB , EvansDN , RhodesJ , EvansBK , HughesBR , LeeMG , et al. Metabolism and urinary excretion of 5‐amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut1987;28(2):196‐200. ">Myers 1987</a>), and does not reach the distal bowel in therapeutic concentrations. Several 5‐ASA formulations have been designed in order to inhibit proximal absorption and enable delivery to distal sites of inflammation. The protection of 5‐ASA compound can be achieved either by linking it to itself or to another carrier or by using slow release preparations of 5‐ASA. Different 5‐ASA preparations may allow delivery of 5‐ASA to different locations in the gastrointestinal tract. </p> </section> <section id="CD008414-sec-0026"> <h3 class="title" id="CD008414-sec-0026">How the intervention might work</h3> <p>5‐aminosalicylic acid agents are locally acting, anti‐inflammatory compounds that reduce inflammation of the colonic mucosa with release profiles that vary among various commercially available formulations (<a href="./references#CD008414-bbs2-0025" title="AbinusawaA , TenjarlaS . Release of 5‐aminosalicylic Acid (5‐ASA) from mesalamine formulations at various pH Levels. Advances in Therapy2015;32(5):477‐84. ">Abinusawa 2015</a>). However, in order to express an antiinflammatory effect seen through a negative regulation of cyclooxygenase and lipoxygenase pathways and prevention of prostaglandin and leukotrienes formation (<a href="./references#CD008414-bbs2-0040" title="LigumskyM , KarmeliF , SharonP , ZorU , CohenF , RachmilewitzD . Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology1981;81:444–9. ">Ligumsky 1981</a>), and increased peroxisome proliferator‐activated receptors expression (<a href="./references#CD008414-bbs2-0050" title="RousseauxC , LefebvreB , DubuquoyL , LefebvreP , RomanoO , AuwerxJ , et al. Intestinal antiinflammatory effect of 5‐aminosalicylic acid is dependent on peroxisome proliferator‐activated recepter‐y. Journal of Experimental Medicine2005;201(8):1205‐15. ">Rousseaux 2005</a>), 5‐ASA agents must be able to directly target the terminal ileum and colon. The commonly used oral 5‐ASA formulations include azo compounds, mesalazine delayed‐release agents and mesalazine slow‐release formulations. For azo compounds, a carrier molecule is linked to 5‐ASA by an azo bond using the same principle as sulphasalazine. Olsalazine consists of two molecules of 5‐ASA joined together, whilst balsalazide is a prodrug in which a 5‐ASA molecule is linked to 4‐aminobenzoyl‐B‐alanine, an inert and biologically inactive carrier molecule. Like sulphasalazine, the azo bond of these drugs is split in the colon by bacterial azo reductases, releasing 5‐ASA to exert local therapeutic activity. The 5‐ASA compound of immediate‐release oral mesalamine formulations is quickly absorbed in the upper gastrointestinal tract resulting in a negligible clinical effect (<a href="./references#CD008414-bbs2-0049" title="RasmussenSN , BondesenS , HvidbergEF . 5‐Aminosalicylic acid in a slow‐release preparation. Advances in Therapy2015;32:477‐84. ">Rasmussen 1982</a>; <a href="./references#CD008414-bbs2-0055" title="ShafiiA , ChowdhuryJR , DasKM . Absorption, enterohepatic circulation, and excretion of 5‐aminosalicylic acid in rats. American Journal of Gastroenterology1982;77:297–9. ">Shafil 1982</a>). Therefore, in order to provide stable delivery of the active 5‐ASA compound to the colon, controlled‐release and pH dependent oral mesalamine agents have been developed (<a href="./references#CD008414-bbs2-0049" title="RasmussenSN , BondesenS , HvidbergEF . 5‐Aminosalicylic acid in a slow‐release preparation. Advances in Therapy2015;32:477‐84. ">Rasmussen 1982</a>). Mesalazine delayed‐release agents (Eudragit‐coated) are coated with a resin designed to dissolve at a certain pH which gradually increases from the stomach (approximate pH = 2) via the small intestine (pH = 6) to the colon (pH = 7 to 8) (<a href="./references#CD008414-bbs2-0048" title="NugentSG , KumarD , RamptonDS , EvansDF . Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut2001;48:571‐7. ">Nugent 2001</a>). Asacol is coated with Eudragit S which dissolves above pH 7.0 to release 5‐ASA in the terminal ileum and colon. Eudragit‐L coated mesalazine (Salofalk) dissolves above pH 6.0 to release 5‐ASA in the terminal ileum and colon. Mesalazine slow‐release formulations include drugs such as Pentasa. Pentasa contains microgranules of 5‐ASA that are individually coated with ethylcellulose. The microgranules are dispersed in the gut providing a slow,steady release of 5‐ASA along the length of the intestine from the upper small bowel to the colon. These 5‐ASA preparations were intended to avoid the adverse side effects of sulphasalazine whilst maintaining its therapeutic benefits. </p> <p>Several randomised controlled trials have been published, comparing various 5‐ASA agents to placebo, with contradicting results (<a href="./references#CD008414-bbs2-0033" title="deFranchisR , OmodeiP , RanziT , BrignolaC , RoccaR , PradaA , et al. Controlled trial of oral 5‐aminosalicylic acid for the prevention of early relapse in Crohn's disease. Alimentary Pharmacology &amp; Therapeutics1997;11(5):845‐52. ">De Franchis 1997</a>; <a href="./references#CD008414-bbs2-0034" title="GendreJP , MaryJY , FlorentC , ModiglianiR , ColombelJF , SouleJC , et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo‐controlled study. The Groupe d'Etudes Therapeutiques des Inflammatoires Digestives (GETAID). Gastroenterology1993;104(2):435‐9. ">Gendre 1993</a>; <a href="./references#CD008414-bbs2-0042" title="MahmudN , KammMA , DupasJL , JewellDP , O'MorainCA , WeirDG , et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut2001;49(4):552‐6. ">Mahmud 2001</a>). Three previous meta‐analyses have suggested that 5‐ASA may be beneficial for the maintenance of medically‐induced remission in Crohn’s disease (<a href="./references#CD008414-bbs2-0031" title="CammaC , GiuntaM , RosselliM , CottoneM . Mesalamine in the maintenance treatment of Crohns disease: A meta‐analysis adjusted for confounding variables. Gastroenterology1997;113(5):1465‐73. ">Camma 1997</a>; <a href="./references#CD008414-bbs2-0043" title="MessoriA , BrignolaC , TralloriG , RampazzoR , BardazziG , BelloliC , et al. Effectiveness of 5‐aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta‐analysis. American Journal of Gastroenterology1994;89(5):692‐8. ">Messori 1994</a>; <a href="./references#CD008414-bbs2-0056" title="SteinhartAH , HemphillD , GreenbergGR . Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta‐analysis. American Journal of Gastroenterology1994;89(12):2116‐24. ">Steinhart 1994</a>), but in one report the only bibliographic database searched was MEDLINE (<a href="./references#CD008414-bbs2-0031" title="CammaC , GiuntaM , RosselliM , CottoneM . Mesalamine in the maintenance treatment of Crohns disease: A meta‐analysis adjusted for confounding variables. Gastroenterology1997;113(5):1465‐73. ">Camma 1997</a>), and another meta‐analysis did not report how the quality of included studies was assessed (<a href="./references#CD008414-bbs2-0043" title="MessoriA , BrignolaC , TralloriG , RampazzoR , BardazziG , BelloliC , et al. Effectiveness of 5‐aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta‐analysis. American Journal of Gastroenterology1994;89(5):692‐8. ">Messori 1994</a>). A Cochrane review on the use of 5‐ASA agents for the maintenance of medically‐induced remission in Crohn’s disease completed in 2005 concluded that there was no evidence to suggest that 5‐ASA preparations were superior to placebo for the maintenance of medically‐induced remission in Crohn’s disease (<a href="./references#CD008414-bbs2-0026" title="AkobengAK , GardenerE . Oral 5‐aminosalicylic acid for maintenance of medically induced remission in Crohns disease. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD003715.pub2] ">Akobeng 2005</a>). This review was recently updated and again there was no evidence to suggest that 5‐ASA was efficacious in this setting, although these agents had a good safety profile (<a href="./references#CD008414-bbs2-0027" title="AkobengAK , ZhangD , GordonM , MacDonaldJK . Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD003715.pub3] ">Akobeng 2016</a>). </p> </section> <section id="CD008414-sec-0027"> <h3 class="title" id="CD008414-sec-0027">Why it is important to do this review</h3> <p>5‐ASA agents have been studied extensively in the post‐operative setting, and a previous meta‐analysis published in 1997 suggested that 5‐ASA agents may be beneficial for the prevention of postoperative recurrence in Crohn’s disease (<a href="./references#CD008414-bbs2-0031" title="CammaC , GiuntaM , RosselliM , CottoneM . Mesalamine in the maintenance treatment of Crohns disease: A meta‐analysis adjusted for confounding variables. Gastroenterology1997;113(5):1465‐73. ">Camma 1997</a>). However, at least one subsequent multicentre randomised controlled trial failed to show an overall benefit compared with placebo (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>). A previous review by this team in 2011 found evidence that 5‐ASA may be efficacious and safe in the post‐surgical setting (<a href="./references#CD008414-bbs2-0036" title="GordonM , NaidooK , ThomasAG , AkobengAK . Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD008414.pub2] ">Gordon 2011</a>). However, an updated systematic review using the Cochrane Collaboration format is indicated to summarise the current evidence on the use of 5‐ASA agents for the maintenance of surgically‐induced remission in Crohn’s disease. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008414-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008414-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008414-sec-0108">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008414-sec-0028"></div> <p>The primary objective was to evaluate the efficacy of 5‐ASA agents for the maintenance of surgically‐induced remission in Crohn’s disease. The secondary objective was to determine the frequency of adverse events associated with the use of 5‐ASA agents for the maintenance of remission in Crohn’s disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008414-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008414-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008414-sec-0109">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008414-sec-0029"></div> <section id="CD008414-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008414-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials which compared sulphasalazine and 5‐ASA agents to either placebo or another intervention, with treatment durations of at least three months were considered for inclusion. </p> </section> <section id="CD008414-sec-0032"> <h4 class="title">Types of participants</h4> <p>Participants of any age and sex with a diagnosis of Crohn’s disease confirmed by any established method who were in remission following surgery, defined by a recognized Crohn’s disease activity index or endoscopy, or patients who have undergone a curative surgical resection, as defined by the authors of the primary studies were considered for inclusion. Trials conducted in any setting (e.g. single‐centre or multicentre) with no language restrictions were considered for inclusion. </p> </section> <section id="CD008414-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The controlled interventions of interest included any randomised controlled trial which compared any oral 5‐ASA agents to a no treatment control, placebo or another active intervention for maintenance of surgically‐induced remission in Crohn’s disease. For this review, studies employing sulphasalazine preparations have been analysed separately, given that these agents have a unique biochemical structure to other 5‐ASA preparations. For the main analysis, all other 5‐ASA preparations were considered together and for the purposes of the nomenclature of this review, were termed '5‐ASA'. Studies that compared sulphasalazine or 5‐ASA agents to an intervention that focuses on enteral nutrition, oral nutrient supplementation, herbal medicines, medical foods, probiotics or parental nutrition, as well as dose optimisation studies were excluded. </p> </section> <section id="CD008414-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD008414-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measure was clinical relapse as defined by the primary studies. We accepted the authors’ definitions of what constitutes a clinical relapse. </p> </section> <section id="CD008414-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcome measures included:<br/> 1) Endoscopic recurrence, as defined by the original studies;<br/> 2) Radiologic relapse, as defined by the original studies;<br/> 3) Adverse events;<br/> 4) Serious adverse events;<br/> 5) Withdrawal due to adverse events; and<br/> 6) Health related quality of life (HRQoL). </p> <p>We reported outcome measures at the last time point available (assumed to be at the end of follow‐up if not specified) and the time point specified in the methods as being of primary interest (if this was different from the latest time point available). However, we also indicated when studies report outcomes at other time points. </p> </section> </section> </section> <section id="CD008414-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008414-sec-0038"> <h4 class="title">Electronic searching</h4> <p>We searched the following databases from inception to 16 July 2018:</p> <p>1. MEDLINE (National Library of Medicine, Bethesda, USA);</p> <p>2. Embase (Elsevier Science, New York, USA);</p> <p>3. CENTRAL; and</p> <p>4. Cochrane IBD Group Specialized Register.</p> <p>No restrictions were placed on publication dates or language. Note that the searches were designed to include RCTs conducted in adults and children, but exclude trials that compare 5‐ASA to oral nutrition supplements (enteral nutrition drinks, tube feeds), medical foods, probiotics, parenteral nutrition or a combination of these modalities. The search strategies are reported in <a href="./appendices#CD008414-sec-0093">Appendix 1</a>. </p> </section> <section id="CD008414-sec-0039"> <h4 class="title">Searching other resources</h4> <section id="CD008414-sec-0040"> <h5 class="title">Reference searching</h5> <p>We searched reference lists from included articles and any existing relevant reviews.</p> </section> <section id="CD008414-sec-0041"> <h5 class="title">Abstracts of major gastroenterology meetings</h5> <p>A manual search of abstracts submitted to major gastroenterology meetings (2015 to 2018) was performed for the following journals to identify more trials that may have not been published in full at the time of the review:<br/> 1. Gastroenterology (American Gastroenterological Association);<br/> 2. Gut (British Society of Gastroenterology);<br/> 3. American Journal of Gastroenterology (American College of Gastroenterology);<br/> 4. Canadian Journal of Gastroenterology (Canadian Association of Gastroenterology);<br/> 5. Journal of Pediatric Gastroenterology and Nutrition (European Society of Paediatric Gastroenterology, Hepatology and Nutrition); and<br/> 6. Journal of Pediatric Gastroenterology and Nutrition (North American Society of Paediatric Gastroenterology, Hepatology and Nutrition). </p> <p>When a relevant abstract was identified, details of the full study methodology and results were requested from the authors in order to allow a thorough assessment of the quality of identified studies. Abstracts for which this information could not be obtained were excluded. </p> </section> <section id="CD008414-sec-0042"> <h5 class="title">Trials Registers</h5> <p>We searched clinicaltrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) for ongoing studies. </p> </section> </section> </section> <section id="CD008414-sec-0043"> <h3 class="title" id="CD008414-sec-0043">Data collection and analysis</h3> <section id="CD008414-sec-0044"> <h4 class="title">Selection of studies</h4> <p>Two authors (MG and TGH) independently reviewed each article at each stage of selection including title screening, abstract screening and full‐text review. Included and excluded studies were recorded. </p> <p>Step 1. Title screening using the above search strategy, papers (or abstracts) that appeared to have even a minor possibility of inclusion were selected by two authors (MG and TGH). Adjudication did not occur at the title screening stage and studies that were ambiguous were included by default. </p> <p>Step 2. Abstract screening: involved selection of articles that report studies with a reasonable possibility of inclusion. Differences in assessment for inclusion were resolved by discussion between the two independent investigators (MG and TGH). Adjudication did not occur at the abstract screening state. </p> <p>Step 3. Full‐text review involved selection of articles based on careful examination of the full report. Differences in assessment for inclusion were resolved by discussion between the two independent investigators. Adjudication was performed as needed by a third author (ZIE). </p> </section> <section id="CD008414-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>Two authors (ZEI and TGH) independently extracted and recorded the data using a data extraction form developed to extract information on relevant features and results of the included studies. Extracted data included the following items: </p> <p> <ul id="CD008414-list-0001"> <li> <p>Study design (type of RCT, setting, number of interventions, year, author's contact details); </p> </li> <li> <p>Population characteristics: age, sex, disease distribution, disease duration, site of disease, medication, type and time since operation, total number of patients originally assigned to each treatment group; </p> </li> <li> <p>Intervention: type and dose of agent;</p> </li> <li> <p>Control: no active treatment, placebo, other drugs;</p> </li> <li> <p>Concurrent medications; and</p> </li> <li> <p>Outcomes: time of assessment, length of follow‐up, type of Crohn's disease activity index used, definitions of remission and relapse, site of surgery, relapse rates, adverse events. </p> </li> </ul> </p> </section> <section id="CD008414-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (ZEI and TGH) independently assessed the risk of bias using the Cochrane risk of bias tool (<a href="./references#CD008414-bbs2-0038" title="HigginsJPT , GreenS (Editors) . Cochrane Handbook for Systematic Reviews of Interventions [Version 5.1.0]. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). Adjudication was performed as needed by a third author (MG). Each domain was assessed as having a low, moderate, high, or unclear risk of bias. Domaines assessed include: </p> <p> <ul id="CD008414-list-0002"> <li> <p>Sequence generation (i.e. was the allocation sequence adequately generated?);</p> </li> <li> <p>Allocation sequence concealment (i.e. was allocation adequately concealed?);</p> </li> <li> <p>Blinding of participants and personnel and outcome assessors (i.e. was knowledge of the allocated intervention adequately prevented during the study?); </p> </li> <li> <p>Incomplete outcome data (i.e. were incomplete outcome data adequately addressed?);</p> </li> <li> <p>Selective outcome reporting (i.e. are reports of the study free of suggestion of selective outcome reporting?); and </p> </li> <li> <p>Other potential sources of bias (i.e. was the study apparently free of other problems that could put it at a high risk of bias?). </p> </li> </ul> </p> <p>Each domain followed standard definitions used for Cochrane systematic reviews (<a href="./references#CD008414-bbs2-0038" title="HigginsJPT , GreenS (Editors) . Cochrane Handbook for Systematic Reviews of Interventions [Version 5.1.0]. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). Based on the aggregate assessment of these items, study quality was rated as good (low risk of bias), fair, or poor (high or unclear risk of bias). Study authors were contacted for further information when insufficient information was provided to determine the risk of bias. </p> <section id="CD008414-sec-0047"> <h5 class="title">Summary of findings tables</h5> <p>The overall strength of evidence supporting the primary outcome and selected secondary outcomes was assessed using the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) criteria (<a href="./references#CD008414-bbs2-0037" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD008414-bbs2-0054" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. In: HigginsJPT , GreenS , editor(s) . Chapter 12: Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). For the 'Summary of findings' tables, we included the following outcomes: clinical relapse, endoscopic recurrence, radiologic relapse, adverse events, serious adverse events, study withdrawal due to adverse events and health‐related quality of life. Though evidence from RCTs starts as high quality, the quality of the evidence can be downgraded due to: risk of bias, indirect evidence, inconsistency (unexplained heterogeneity), imprecision and publication bias. Taking all of these factors into account, we rated the overall quality of evidence as follows: </p> <p> <ul id="CD008414-list-0003"> <li> <p>High ‐ we are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p>Moderate ‐ we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; </p> </li> <li> <p>Low ‐ our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect; or </p> </li> <li> <p>Very low. We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> <section id="CD008414-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, we calculated the risk ratio (RR) estimates and associated two‐sided 95% confidence intervals (CI). For nominal or ordinal outcomes, we planned to calculate the RR with corresponding 95% for each category relative to a reference category. For continuous outcomes, we calculated the mean difference (MD) and corresponding 95% CI. </p> </section> <section id="CD008414-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. We planned to include cross‐over trials if data were available from the first phase of the study (i.e. before cross‐over occurred). For outcomes where events recur (e.g. clinical relapses, adverse events), we calculated the proportion of patients who experienced at least one event. Individual events were not counted separately. The studies were otherwise not anticipated to have repeated observations of outcomes or multiple treatment events. </p> </section> <section id="CD008414-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>Information on how each trial handled missing data was recorded. When a study appeared to collect and not report on all primary outcomes of interest, the original investigators were contacted to request missing data. If the original investigators did not provide the data, this would be noted in the systematic review. For studies with missing dichotomous data, a separate intention‐to‐treat analysis was performed where participants with missing data were assumed to have been treatment failures. For the main analysis, the total number of patients was used as a denominator. It was assumed that participants who dropped out of the study, and on whom there was no post withdrawal information, had relapsed during the study period. For missing continuous data, we used an available case analysis. </p> </section> <section id="CD008414-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity and inconsistency was assessed to ensure the validity of the analysis. Initially heterogeneity was assessed through visual inspection of forest plots and the calculation of the Chi² and I² statistics (<a href="./references#CD008414-bbs2-0030" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Introduction to meta‐analysis. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2009. ">Boreinstein 2009</a>). For studies that had qualitative homogeneity, statistical heterogeneity was assessed using the Chi² test (P value &lt; 0.10 was considered statistically significant heterogeneity). The degree of heterogeneity across studies was estimated using the I² statistic. An I² of 25% or less was considered low heterogeneity, 26 to 50% was considered moderate heterogeneity, and 50% and greater was considered substantial heterogeneity. Possible explanations for heterogeneity were examined where sufficient data were available, including factors such as participant characteristics (e.g. age, sex), disease condition severity, treatment type and dose, and healthcare system/country. Where appropriate, these factors were investigated further through sub‐group analyses and meta‐regression (<a href="./references#CD008414-bbs2-0030" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Introduction to meta‐analysis. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2009. ">Boreinstein 2009</a>). Sensitivity analyses were used to explore possible causes of methodological heterogeneity, where sufficient data were available (<a href="./references#CD008414-bbs2-0057" title="SuttonAJ , AbramsKR , JonesDR , SheldonTA , SongF . Methods for meta‐analysis in medical research. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2000. ">Sutton 2000</a>). This included assessing the effects of studies that may be affected by factors such as risk of bias associated with allocation concealment, high loss to follow‐up or lack of blinding in assessment of outcomes. </p> </section> <section id="CD008414-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>If there were an appropriate number of studies in a pooled analysis (i.e. &gt; 10 studies), we planed to investigate potential publication bias using funnel plots (trial effects versus trial size). However, the number of studies in each comparison group was smaller than 10. </p> </section> <section id="CD008414-sec-0053"> <h4 class="title">Data synthesis</h4> <p>The Cochrane Collaboration review manager (RevMan) software (version 5.3.5) was used for data analyses. Data were analysed according to the intention‐to‐treat principle. Patients with final missing outcomes were assumed to have relapsed. </p> <p>Analyses were grouped by type of intervention treatment (e.g. 5‐ASA versus purine analogues, 5‐ASA versus placebo). Studies were synthesised through a narrative review with tabulation of results of included studies. Where possible, treatment effects for all comparisons and outcomes were synthesized through meta‐analyses, with the approach taken dependant on the outcome assessed and the data available (<a href="./references#CD008414-bbs2-0030" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Introduction to meta‐analysis. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2009. ">Boreinstein 2009</a>). Although the primary outcome assessed focused on the dichotomous outcomes of clinical relapse and endoscopic recurrence, secondary outcomes involved other data types. </p> </section> <section id="CD008414-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to assess the impact of potential effect modifiers such as age of patients (paediatric versus adult studies) and length of follow‐up (12 months or less versus greater than 12 months). However, there were insufficient data for these analyses. </p> </section> <section id="CD008414-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>Methodological heterogeneity was to be examined through sensitivity analysis, including components of risk of bias and dose of 5‐ASA, however, this was not possible due to insufficient data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008414-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008414-sec-0056"></div> <section id="CD008414-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD008414-sec-0058"> <h4 class="title">Results of the search</h4> <p>The results of the updated search conducted on 16 July 2018 are reported in the PRISMA flow diagram (See <a href="#CD008414-fig-0001">Figure 1</a>). We identified 713 records of which 546 citations remained after duplicates were removed. Following title and abstract screening, 33 potentially relevant reports were identified and subjected to further scrutiny. Fourteen RCTs (1867 participants) reported in 23 articles satisfied the inclusion criteria and were included in this review (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>). One study was awaiting classification (<a href="./references#CD008414-bbs2-0024" title="NCT00976690 . Comparison azathioprine to mesalazine for the prevention of postoperative recurrence in the Crohn disease (IMURELPOST). clinicaltrials.gov/ct2/show/NCT00976690 (accessed 14 September 2009). ">NCT00976690</a>). The rest of the studies were excluded. Detailed information about these studies are presented in the <a href="./references#CD008414-sec-0100" title="">Characteristics of included studies</a>, <a href="./references#CD008414-sec-0101" title="">Characteristics of excluded studies</a>, and additional <a href="#CD008414-tbl-0007">Table 1</a> and <a href="#CD008414-tbl-0008">Table 2</a>, and are summarised below. </p> <div class="figure" id="CD008414-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD008414-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <div class="table" id="CD008414-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summury of interventions and outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse</b> </p> <p><b>Events/</b> </p> <p><b>Serious</b> </p> <p><b>adverse events/ Withdrawal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2 mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 32<b>/</b>71 vs. 35/71 </p> <p><b>Surgical:</b> 25/71 vs. 18/71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 27/71 vs. 18/71 </p> <p><b>SAE:</b> 6/71 vs. 15/71 </p> <p><b>Withdrawal:</b> 6/71 vs. 15/71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo tablets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 13/44 vs. 14/43 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/44 vs. 3/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(2.4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse:</b> 20/55 vs. 28/55 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 2/55 vs. 2/55 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine</p> <p>(4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine</p> <p>(2.4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 17/101 vs. 27/101 </p> <p><b>Endoscopic &gt;1:</b> 45/101 vs. 59/105 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 2/101 vs. 2/105 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulfasalazine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse:</b> </p> <p>Total 0‐36 months: 89/111 vs. 99/121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Claversal (1000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> <p>(1000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic:</b> 38/65 vs. 40/61 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 5/65 vs. 3/61 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐Mercaptopurine (50 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 32/47 vs. 33/44 vs.35/40 </p> <p><b>Endoscopic rate:</b> % (CI) </p> <p><b>Radiographic rate:</b> % (CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 9/47 vs. 6/44 vs. 4/40 </p> <p><b>SAE:</b> 2/47 vs. 0/44 vs. 0/40 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 47/154 vs. 59/170 </p> <p><b>Endoscopic:</b> 133/154 vs. 134/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SAE:</b> 8/154 vs. 9/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptomatic relapse:</b> 35/88 vs. 44/81 </p> <p><b>Endoscopic and radiologic rate:</b> significantly decreased in Group1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 7/88 vs. 10/81 </p> <p><b>SAE:</b> 1/88 vs. 0/81 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2.0 to 2.5 mg/kg/day) + Placebo mesalazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine (4 g/day) +</p> <p>Placebo azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean IBDQ change compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 34/37 vs. 32/41 </p> <p><b>SAE:</b> 0/37 vs. 10/41 </p> <p><b>Withdrawal:</b> 1/37 vs. 10/41 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab (160 mg at week 0, 80 mg at 2 weeks and 40 mg/week thereafter)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2 mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical by CDAI:</b> 1/16 vs.12/17 vs. 9/18 </p> <p><b>Endoscopic:</b> 1/16 vs. 11/17 vs. 15/18 </p> <p><b>Radiologic:</b> 1/16 vs. 13/17 vs. 15/18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ &gt;170:</p> <p>14/16 vs 2/17 vs 3/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b>11/16 vs. 14/17 vs. 14/18 </p> <p><b>Withdrawal:</b>1/16 vs. 1/17 vs. 0/18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 3/31 vs.8/35 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ score: significant decline in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suphasalazine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 6/32 vs. 11/34 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 0/32 vs. 1/34 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE = adverse events; CDAI = Crohn's disease activity index; ; g = gram; IBDQ = inflammatory bowel disease questionnaire; mg = milligram; N/A = not applicable; SAE = serious adverse events; </p> </div> </div> <div class="table" id="CD008414-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Key study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from surgery till recruitment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Site of surgery % /</b> </p> <p><b>*exclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic / histological recurrence definition/ other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sulfasalazine vs Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFZ 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediately after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileocolon 92; Ileum 2; colon 6</p> <p>*non‐standard policy resection (radical or non‐radical)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proven by radiology, endoscopy or operation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFZ 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Special control charts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA vs no treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 2.4 g/day (24 mo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>*disease localisation to the jejunum, proximal ileum, left colon or ano‐rectum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐asa vs placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day</p> <p>vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 56, ileocaecal 46</p> <p>*surgery other than in ileal or ileocaecal region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standardised form for description of endoscopic lesions by type and characteristics</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 1.5 g/day vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 44 ; colonic 6; ileocolonic 48; Anoperineal lesion 12.</p> <p>* permanent stoma, small intestinal resection of more than 100 cm prior to the pretrial operation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before postoperative hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical recurrence grading &gt;2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i &gt; 2</p> <p><b>Radiographic relapse:</b> radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 4 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIeal 49; ileocolonic 56, colonic 5.</p> <p>* short bowel syndrome, presence of an ileocolonic stoma, more than 3 surgeries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 250 and CDAI &gt;200 but min 60 points increase for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 50, MES 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 8 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIeal 21; ileocolonic 46, colonic 33.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe symptoms to warrant treatment and radiological or endoscopic evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of endoscopic or radiological evidence of disease and included both asymptomatic and symptomatic patients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 49, ileocolonic 50, unknown 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;150 as well as the absolute value of at least 60 points higher than baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p><b>HRQL: IBDQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA vs AZA or 6‐MP</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 mg/kg/day vs. AZA 2 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Max 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small bowel only 25.3; Colon 5.6; Small bowel and colon 9.8; upper gastrointestinal tract 16.2 </p> <p>*surgical procedures other than conservative surgery or for perianal disease only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p><b>Surgical relapse:</b> need for another surgical procedure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day vs. 6‐MP 50 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>before postoperative hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical recurrence grading &gt;2 (Hanauer et al)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiographic relapse:</b> radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 4g/day vs. AZA 2 mg/kg/day (52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>* Short bowel syndrome, an ileocolonic stoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>HRQL: IBDQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEZ 3 g/day vs. AZA 2 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51</p> <p>* fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 clinical recurrence grading scale ( Hanauer et al)</p> <p>2. CDAI &gt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiologic relapse</b> : ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQL:</b> IBDQ &gt; 170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA vs anti TNF‐α</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEZ 3 g/day vs. Adalimumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51</p> <p>* fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 on the clinical recurrence grading scale by Hanauer</p> <p>2. CDAI &gt;200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiologic relapse</b> : ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQL:</b> IBDQ &gt; 170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA VS 5‐ASA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 g/day MES vs. 2.4 g/day MES (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 64; Ileum/caecum/ascending colon 36</p> <p>* disease localization to jejunum, proximal ileum, transverse colon, left colon or anorectum </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 150 points or an increase in CDAI score of + 100 points from baseline.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 1</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>g = gram; mg = milligram; kg = kilogram; SFZ = sulphasalazine; MES = mesalamine; MEZ = mesalazine; 6‐MP = 6‐mercaptopurine; IBDQ = inflammatory bowel disease questionnaire; HRQL = health related quality of life; N/A = not applicable </p> <p>AZA = azathioprine; CDAI = Crohn's disease activity index</p> </div> </div> </section> <section id="CD008414-sec-0059"> <h4 class="title">Included studies</h4> <section id="CD008414-sec-0060"> <h5 class="title">Study design and setting</h5> <p>The 14 RCTs (23 reports) included in this review were single or multi‐centre studies with a duration ranging from 12 weeks (<a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>) to a maximum of 72 months (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>). The included studies were published between 1978 and 2017. There were two single‐centre studies, both conducted in Italy (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). The multi‐centre studies were conducted in Germany (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>), Canada (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>), and Italy (<a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>), or as a multinational collaboration of several countries across Europe (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>, <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>) and Europe and the USA (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>). Regarding the trial setting, studies were conducted either in gastroenterology hospitals and medical clinics/centres (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>, or as a collaboration of university clinics and hospitals and medical centres (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a> did not report the trial setting. </p> </section> <section id="CD008414-sec-0061"> <h5 class="title">Participants</h5> <p>The total number of randomised participants included in all 14 trials studies was 1867, with sample sizes ranging between 51 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) and 324 (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>). The participants of the included studies ranged in age from 15 to 70 years. </p> <p>The age of participants was reported in most studies and ranged between an average of 33.6 (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>) to 38.4 years (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>) in 11 trials, while two trials reported age as median (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>). <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a> did not report on participant age. All studies appear to have been be conducted on adult population of both genders, except <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> that included male and female patients aged &gt; 15 years. None of the studies was conducted in paediatric patients only. </p> <p>Maintenance therapy was started less than three months postoperatively in all but two studies. One study randomised patients between 6 to 24 months after surgery (<a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>), while the time from, surgery until the start of the intervention remained unclear in <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>. </p> <p>Interventions were conducted postsurgically in patients with quiescent Crohn’s disease established by generally accepted endoscopic, histological or radiological criteria, except in <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> where diagnosis of clinical remission and relapse was not based on index calculation, but on information collected from special control charts including the presence or absence of symptoms such as fever, diarrhoea, rectal bleeding, abdominal pain, extra‐intestinal manifestations, palpable abdominal masses, fistulae, abscesses and loss of working days. It is important to note that <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a> included participants with subsequent postoperative clinical remission (Crohn's disease activity index CDAI &lt; 200), but with signs of moderate to severe endoscopic recurrence. </p> <p>The use of concurrent treatment was specifically reported in all but three studies (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>). In most of the studies previous treatment with aminosalicylates, metronidazole and any other Crohn’s disease specific treatment had to be discontinued before surgery, while concomitant treatment for Crohn’s disease during the trial was prohibited. However, corticosteroids were allowed to be tapered by standardized stepwise dose reductions in <a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>, <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>, and <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>. Symptomatic treatment with antacids, antidiarrhoeal or spasmolytic medication on demand was permitted in three studies (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>), but had to be scrupulously recorded. Continous use of nonsteroidal anti‐inflammatory drugs was prohibited and only occasional use of paracetamol and tramadol was allowed in <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>. </p> </section> <section id="CD008414-sec-0062"> <h5 class="title">Interventions</h5> <p>Twelve of the included studies were parallel two arm trials with the exception of <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> and <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>, both of which included three intervention arms. The studies compared the efficacy of sulphasalazine and other oral 5‐aminosalicylic acid treatments to no treatment, placebo or another active treatment. Given its unique biochemical structure, interventions utilising sulphasalazine were analysed separately from the rest of the oral 5‐ASA preparations. Detailed information on study interventions are reported in additional <a href="#CD008414-tbl-0007">Table 1</a> and <a href="#CD008414-tbl-0008">Table 2</a> and are summarised as follows: </p> <p> <ul id="CD008414-list-0004"> <li> <p>Studies comparing sulfasalazine versus placebo (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>); </p> </li> <li> <p>Studies comparing 5‐ASAs to a no treatment control (<a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>); </p> </li> <li> <p>Studies comparing 5‐ASAs to placebo (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>); </p> </li> <li> <p>Studies comparing 5‐ASAs to purine antimetabolites (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>); </p> </li> <li> <p>Studies comparing 5‐ASAs to anti‐tumour necrosis factor‐alpha antagonists (TNF‐ɑ) (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>); and </p> </li> <li> <p>Studies comparing high dose (4 g/day) 5‐ASA to low dose (2.4 g/day) 5‐ASA (<a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>). </p> </li> </ul> </p> </section> <section id="CD008414-sec-0063"> <h5 class="title">Outcomes</h5> <p>Outcome data where reported at multiple time points in six studies (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>), and at a single time point in eight studies (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). We disregarded follow‐up data in studies which continued to monitor participants beyond the end of treatment. </p> <p>Studies reported the following outcomes:</p> <section id="CD008414-sec-0064"> <h6 class="title">Primary outcome</h6> <p>Thirteen studies included clinical relapse as the primary outcome (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>). </p> </section> <section id="CD008414-sec-0065"> <h6 class="title">Secondary outcomes</h6> <p>Secondary outcomes reported in the primary studies include the following:</p> <p>1) Endoscopic recurrence (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>); </p> <p>2) Endoscopic and/or radiological recurrence combined (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>); </p> <p>3) Radiological relapse (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>); </p> <p>4) Surgical relapse (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>); </p> <p>5) Adverse events (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>); </p> <p>6) Serious adverse events (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>); </p> <p>7) Withdrawal due to adverse events (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>); and </p> <p>8) HRQoL (<a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). </p> </section> </section> <section id="CD008414-sec-0066"> <h5 class="title">Funding and declaration of interest</h5> <p>Seven studies reported support from pharmaceutical companies (<a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>), but only one study included a declaration of conflicts of interest (<a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>). The study authors were contacted to clarify the role of these pharmaceutical companies: the authors of two studies confirmed that the companies had no role in the study design, data analysis or writing of the paper (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>), whereas the remaining authors did not respond. Funding and conflict of interest was not reported in four studies (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>,<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>), but our attempts to clarify this by contacting the authors were unsuccessful. </p> </section> </section> <section id="CD008414-sec-0067"> <h4 class="title">Excluded studies</h4> <p>Nine studies were excluded for various reasons. These studies are listed in <a href="./references#CD008414-sec-0101" title="">Characteristics of excluded studies</a> table and summarised as follows: </p> <p> <ul id="CD008414-list-0005"> <li> <p>Four were classified as non‐randomised controlled trials (<a href="./references#CD008414-bbs2-0015" title="DumoisRA , HerreraJL . Can postoperative relapse of Crohn's disease be prevented?. American Journal of Gastroenterology2001;96:249. ">Dumois 2001</a>; <a href="./references#CD008414-bbs2-0016" title="EweK . Effectiveness of Azulfidine/Salazopyrin in the postoperative prevention of recurrence in Crohn disease. Zeitschrift fur Gastroenterologie1981;19:41‐4. ">Ewe 1981</a>; <a href="./references#CD008414-bbs2-0018" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDB , et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology1997;113(6):1823‐7. ">McLeod 1997</a>; <a href="./references#CD008414-bbs2-0023" title="OrlandoA , MocciaroF , ScimecaD , RispoA , ScribanoML , TestaA , et al. Early post‐operative endoscopic recurrence in Crohn's disease patients: Data from a large prospective Italian multicenter cohort. Gastroenterology2012;1:S259. ">Orlando 2012</a>); </p> </li> <li> <p>Four trials did not meet intervention inclusion criteria (<a href="./references#CD008414-bbs2-0017" title="ISRCTN84003996 . Efficacy of mesalazine to prevent relapse in paediatric Crohn’s disease. isrctn.com/ISRCTN84003996 (accessed 10 March 2008). ">ISRCTN84003996</a>; <a href="./references#CD008414-bbs2-0019" title="NCT00225810 . A study comparing the acceptability of Pentasa® sachets versus Pentasa® tablets in children with Crohn's disease. clinicaltrials.gov/ct2/show/NCT00225810 (accessed 26 September 2005). ">NCT00225810</a>; <a href="./references#CD008414-bbs2-0020" title="NCT00245505 . The effect on mucosal healing with Pentasa sachet in mild to moderate active &quot;Drug: Crohn's Disease&quot;. clinicaltrials.gov/ct2/show/NCT00245505 (accessed 28 October 2005). ">NCT00245505</a>; <a href="./references#CD008414-bbs2-0021" title="NCT00300118 . Oral Budesonide vs. oral Mesalazine in active Crohn's disease (CD). clinicaltrials.gov/ct2/show/NCT00300118 (accessed 8 March 2006). ">NCT00300118</a>); and </p> </li> <li> <p>One clinical trial was terminated due to the lack of accrual (<a href="./references#CD008414-bbs2-0022" title="NCT01696942 . Cimzia versus Mesalamine for Crohn's recurrence. clinicaltrials.gov/ct2/show/NCT01696942 (accessed 2 October 2012). ">NCT01696942</a>). </p> </li> </ul> </p> </section> </section> <section id="CD008414-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was assessed using the Cochrane risk of bias tool (<a href="./references#CD008414-bbs2-0038" title="HigginsJPT , GreenS (Editors) . Cochrane Handbook for Systematic Reviews of Interventions [Version 5.1.0]. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). The risk of bias was assessed as 'low' in one study (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>), 'unclear' in seven (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>), and as 'high' in rest of the studies (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). Details of the risk of bias assessment for each study are presented in the <a href="./references#CD008414-sec-0100" title="">Characteristics of included studies</a> and <a href="#CD008414-fig-0002">Figure 2</a>, and are summarised below. </p> <div class="figure" id="CD008414-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item of included study." data-id="CD008414-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item of included study. </p> </div> </div> </div> <section id="CD008414-sec-0069"> <h4 class="title">Allocation</h4> <p><b>Random sequence generation</b> </p> <p>In all the included studies allocation of participants to an active treatment, no treatment or placebo was reported as random. Eleven studies reported sufficient information regarding random sequence generation and were judged as being at low risk of bias for this item (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>). The method of randomisation was not adequately described in three studies (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>) and were judged as being at an unclear risk of bias. None of the studies was judged as having a high risk of bias for random sequence generation. </p> <p><b>Allocation concealment</b> </p> <p>Allocation concealment was initially graded adequate and of low risk of bias in five studies (<a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>), and unclear in the rest. The authors of these studies were contacted to clarify allocation concealment, but only one response was received. The response was from Dr. McLeod, who gave further information to confirm her study had adequate allocation concealment, hence later rated as 'low' (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>). The rest of the studies were assessed as having an inadequate description for allocation concealment, and were marked 'unclear' regarding risk of bias for allocation concealment (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>). </p> </section> <section id="CD008414-sec-0070"> <h4 class="title">Blinding</h4> <p><b>Blinding of participants and personnel</b><br/> Three of the studies included had an open‐label study design and were judged as being at high risk of bias for blinding (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). All the remaining studies were described as double‐blind. However, the method of blinding was not described clearly in four studies and these studies were marked as 'unclear' risk of bias (<a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>). These studies either failed to report which parties were blinded or did not report that the placebo was identical to the intervention. Due to the adequate description of blinding methods for both participants and personnel, seven studies were rated as having low risk of bias (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). </p> <p><b>Blinding of outcome assessment</b> </p> <p>One study was judged as having high risk of detection bias as outcome assessors were aware of treatment assignment, which was confirmed by the lead author (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>). Six studies were judged as unclear risk of bias, having failed to adequately describe blinding of outcome assessors (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>)<b>.</b> The remaining seven studies reported sufficient information regarding methods of outcome assessment blinding in order to be judged 'low risk' for detection bias (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>). </p> </section> <section id="CD008414-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>Twelve studies were judged as 'low risk' of bias. Eleven studies reported attrition rates that were low and balanced across groups (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>), and in one study (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>), although the overall attrition rate was high (37%), when compared to the event risk (60%), it was not sufficient to introduce bias. One study was judged to be at high risk of attrition bias due to a high discontinuation rate of 51% (<a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>). <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a> was judged to be at 'unclear' risk of bias as attrition rates were not specifically reported for the sub‐population of interest. </p> </section> <section id="CD008414-sec-0072"> <h4 class="title">Selective reporting</h4> <p>None of the studies had a protocol or trial registration on www.clinicaltrials.gov or the WHO ICTRP with the exception of <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>. Ten studies were judged as being at low risk of bias for reporting all outcomes prespecified in the methods section of the published manuscripts (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). Two studies were judged to be at 'high' risk of bias: one study failed to report on a prespecified outcome (<a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>); and the other study failed to report data on adverse events (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>), which is considered a key outcome for a study of this type. <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> was judged 'unclear' as the results for adverse events were not reported clearly enough to allow analysis and permit a judgement. <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a> was judged as 'unclear' because it was published as an abstract and as a letter and sufficient details about pre‐specified outcomes were not available. </p> </section> <section id="CD008414-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>Twelve studies were judged as being at low risk of bias as there was no indication of other biases occurring (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>; <a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>; <a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> was judged 'unclear' for failing to provide sufficient baseline characteristics of randomised patients, so the presence of any potential imbalances between groups remained uncertain. <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a> was judged as 'unclear' because it was published as an abstract and as a letter and sufficient details about other potential sources of bias were not described. </p> <p>The risk of bias data as summary percentages across all included studies are presented in <a href="#CD008414-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008414-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008414-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> </section> </section> <section id="CD008414-sec-0074"> <h3 class="title" id="CD008414-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD008414-tbl-0001"><b>Summary of findings for the main comparison</b> 5‐ASA compared to no treatment for maintenance of surgically‐induced remission in Crohn's disease</a>; <a href="./full#CD008414-tbl-0002"><b>Summary of findings 2</b> 5‐ASAs compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</a>; <a href="./full#CD008414-tbl-0003"><b>Summary of findings 3</b> High dose 5‐ASA compared to low dose 5‐ASA for maintenance of surgically‐induced remission in Crohn's disease</a>; <a href="./full#CD008414-tbl-0004"><b>Summary of findings 4</b> 5‐ASA compared to purine antimetabolites for maintenance of surgically‐induced remission in Crohn's disease</a>; <a href="./full#CD008414-tbl-0005"><b>Summary of findings 5</b> 5‐ASAs compared to anti TNF‐ɑ for maintenance of surgically‐induced remission in Crohn's disease</a>; <a href="./full#CD008414-tbl-0006"><b>Summary of findings 6</b> Sulphasalazine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</a> </p> <p>Detailed information regarding interventions, treatments and key outcome definitions are presented on <a href="#CD008414-tbl-0008">Table 2</a> and summarised below. </p> <section id="CD008414-sec-0075"> <h4 class="title">5‐ASA versus no treatment</h4> <p><a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a> was the only study that compared 5‐ASA (2.4 g/day) to no treatment and a meta‐analysis was not performed (110 participants; start of intervention: 0‐2 weeks after surgery). </p> <p><b>Primary outcome</b> </p> <p>Clinical relapse at 12 months was defined as a CDAI &gt; 150, and a 100 point increase in CDAI from baseline. Thirty‐six percent (20/55) of participants in the 5‐ASA group relapsed at 12 months compared to 51% (28/55) in the no treatment control group (RR 0.71, 95% CI 0.46 to 1.10, 110 participants, low certainty evidence; See <a href="./references#CD008414-fig-0004" title="">Analysis 1.1</a> and <a href="./full#CD008414-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><b>Secondary outcomes</b> </p> <p><b>Adverse events</b> </p> <p>The effects of 5‐ASAs on adverse events and withdrawal due to adverse events compared to no treatment was uncertain (<a href="./references#CD008414-fig-0005" title="">Analysis 1.2</a>; <a href="./full#CD008414-tbl-0001">summary of findings Table for the main comparison</a>). During the 24 month of intervention, 4% (2/55) of participants experienced adverse events classified as adverse reactions to mesalazine (skin rash, epigastric pain, vomiting, nausea) and they were withdrawn from the trial, compared to 0% (0/55) in the no treatment group (RR 5.00, 95% CI 0.25 to 101.81, 110 participants, 1 study; very low certainty evidence). </p> <p>This study did not report on endoscopic recurrence, radiologic relapse, serious adverse events and HRQoL. </p> </section> <section id="CD008414-sec-0076"> <h4 class="title">5‐ASA versus placebo</h4> <p>Six studies (856 participants; start of intervention: &lt; 8 weeks after surgery) comparing 5‐ASAs (3 to 4 g/day) to placebo were identified (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). </p> <p><b>Primary outcome</b> </p> <p>Five studies reported on clinical relapse. However, the definition of relapse varied across the studies from CDAI &gt; 150 (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>), to CDAI ≥ 250 or CDAI ≥ 200 with a minimum of 60 points increase for 2 weeks in <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>, a clinical recurrence score &gt; 2 as defined by <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>, to severe symptoms that warrant treatment plus radiological or endoscopic evidence of disease (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>). There was moderate certainty evidence that 5‐ASAs are more effective than placebo for preventing clinical relapse (<a href="./references#CD008414-fig-0007" title="">Analysis 2.1</a>, <a href="./full#CD008414-tbl-0002">summary of findings Table 2</a>). During a follow‐up period that ranged from 48 weeks to 72 months, 36% (131/361) of 5‐ASA participants relapsed compared to 43% (160/369) of the placebo participants (RR 0.83, 95% CI 0.72 to 0.96, 730 participants, 5 studies, I² = 0%; moderate certainty evidence). </p> <p><b>Secondary outcomes</b> </p> <p><b>Endoscopic recurrence</b> </p> <p>Endoscopic recurrence data were available for three studies. <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a> defined endoscopic recurrence as a Rutgeerts score i ≥ 1. <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a> defined endoscopic recurrence as a Rutgeerts score i ≥ 2. <a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a> defined endoscopic recurrence as a Rutgeerrts score i <i>&gt;</i> 2. The effect of 5‐ASAs on endoscopic remission was uncertain (<a href="./references#CD008414-fig-0008" title="">Analysis 2.2</a>, <a href="./full#CD008414-tbl-0002">summary of findings Table 2</a>). After 12 weeks to 72 months of follow‐up, 70% (183/263) of participants treated with 5‐ASA had endoscopic recurrence compared to 73% (199/274) in the placebo arm (RR 0.83, 95% CI 0.56 to 1.24, 537 participants, 3 studies, I² = 84%; very low certainty evidence). <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> reported no difference in endoscopic recurrence rates (i ≥ 2) between the mesalamine (48%; 95% CI 30% to 70%) and placebo (42%; 95% CI 21% to 70%) groups at 24 months (reported: HR 1.10; 84 participants). However, the data were insufficient to be included in the meta‐analysis. </p> <p>The effect of 5‐ASAs on radiologic relapse, adverse events, serious adverse events and withdrawals due to adverse events was uncertain (<a href="./full#CD008414-tbl-0002">summary of findings Table 2</a>). </p> <p><b>Radiologic relapse</b> </p> <p>Radiologic relapse rate defined as a radiographic recurrence grading score ≥<i>2</i> was reported in <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>. After 24 months, 46% (95% CI, 29% to 66%) of participants treated with 5‐ASA had radiologic relapse compared to 49% (95% CI, 30% to 72%) in the placebo group (reported: HR 0.61; 84 participants). <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a> reported combined endoscopic and radiologic relapse rate based on the presence of endoscopic or radiological evidence of disease in both symptomatic and asymptomatic patients. At 72 months, mesalamine was more effective in preventing endoscopic and radiologic relapse compared to placebo (RR 0.635, 95% CI 0.44 to 0.91; 169 participants). </p> <p><b>Adverse events, serious adverse events and withdrawal due to adverse events</b> </p> <p>There was no clear difference in the number of participants who experienced adverse events, serious adverse events or were withdrawn from the trial due to adverse events when 5‐ASAs were compared to placebo. Adverse events (<a href="./references#CD008414-fig-0009" title="">Analysis 2.3</a>) were reported in all but one study (<a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). Ten per cent (23/241) of 5‐ASA participants experienced at least one adverse event that was possibly related to treatment compared to 9% (20/225) of placebo participants (RR 1.07; 95% CI 0.60 to 1.91; 466 participants; 4 studies; I² = 0%; low certainty evidence). Reported adverse events included skin lesions, abdominal pain, diarrhoea , vomiting and nausea. Three studies reported serious adverse events that were possibly related to treatment (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>; <a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>; <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>). Over a follow‐up period of 52 weeks to 72 months, approximately an equal proportion of participants from the 5‐ASA (3%; 9/286) and the placebo (3%; 9/291) groups experienced at least one serious adverse event (RR 1.06, 95% CI 0.44 to 2.59, 577 participants, I² = 0%, See <a href="./references#CD008414-fig-0010" title="">Analysis 2.4</a>; low certainty evidence). Reported serious adverse events included postoperative bowel obstruction and pancreatitis. Withdrawal due to adverse events (<a href="./references#CD008414-fig-0011" title="">Analysis 2.5</a>) was reported in three studies (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>). Over a follow‐up period ranging from 12 weeks to 24 months, the withdrawal rate due to adverse events was 10% (16/153) among 5‐ASA participants compared to 7% (10/144) among placebo participants (RR 1.50, 95% CI 0.71 to 3.19, 297 participants, I² =0%; low certainty evidence). Adverse events leading to withdrawal included abdominal pain, pancreatitis and declining creatine clearance. <a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a> reported the total number of withdrawn participants in both intervention arms (6/167) and as data could not be separated it was not included in the meta‐analysis. </p> <p><b>HRQoL</b> </p> <p>Health related quality of life using the IBDQ was evaluated in one study at week 48 (293 participants). However, there were no data reported for further analysis (<a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>). </p> </section> <section id="CD008414-sec-0077"> <h4 class="title">High dose versus low dose 5‐ASA</h4> <p><a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a> was the only study that compared 5‐ASA in doses of 4.0 g/day to 2.4 g/day (206 participants; start of intervention: 0 to 2 weeks after surgery). </p> <p><b>Primary outcome</b> </p> <p>Clinical relapse was defined as a CDAI score higher than 150 or an increase in CDAI of more than 100 points from baseline. There was moderate certainty evidence for the efficacy of mesalamine for maintaining clinical remission when administered in doses of 4.0 g/day and 2.4 g/day (<a href="./references#CD008414-fig-0012" title="">Analysis 3.1</a>; <a href="./full#CD008414-tbl-0003">summary of findings Table 3</a>). At 12 months, the proportion of participants with clinical relapse was 17% (17/101) among the 4 g/day mesalamine group compared to 26% (27/105) in the 2.4 g/day group (RR 0.65, 95% CI 0.38 to 1.13, 206 participants; moderate certainty evidence). </p> <p><b>Secondary outcomes</b> </p> <p><b>Endoscopic recurrence</b> </p> <p>The definition for endoscopic recurrence was based on the presence of typical endoscopic Crohn’s disease lesions in the terminal ileum or anastomosis, graded on the Rutgeer's score &gt; 1. There was moderate certainty evidence regarding the effects of 4.0 g/day compared to 2.4 g/day mesalamine treatment for prevention of endoscopic recurrence (<a href="./references#CD008414-fig-0013" title="">Analysis 3.2</a>; <a href="./full#CD008414-tbl-0003">summary of findings Table 3</a>). After 12 months, the proportion of participants with endoscopic recurrence was 45% (45/101) and 56% (59/105) in the 4.0 g/day and 2.4 g/day mesalamine treated participants respectively (RR 0.79, 95% CI 0.60 to 1.04, 206 participants; moderate certainty evidence). </p> <p><b>Adverse events, serious adverse events and withdrawal due to adverse events</b> </p> <p>Regarging adverse events and withdrawal due to adverse events, the evidence was low certainty (<a href="./references#CD008414-fig-0014" title="">Analysis 3.3</a>; <a href="./full#CD008414-tbl-0003">summary of findings Table 3</a>). At 12 months, approximately an equal proportion of participants from the 4.0 g/day (2%; 2/101) and the 2.4 g/day (2%; 2/105) groups experienced an adverse event and were withdrawn from the study (RR 1.04, 95% CI 0.15 to 7.24, 206 participants; low certainty evidence). Reported adverse events include severe dyspepsia, increase in transaminases and limb cramps. </p> <p><a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a> did not report on serious adverse events and HRQoL. </p> </section> <section id="CD008414-sec-0078"> <h4 class="title">5‐ASA versus purine antimetabolites</h4> <p>A total of five studies compared the efficacy of mesalamine (dose 3 to 4 g/day) to azathioprine (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>), or 6‐mercaptopurine (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>) agents (425 participants; start of intervention: within 4 weeks, except in <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a> (6 to 24 months postoperatively)). Due to the specific inclusion/exclusion criteria in <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a> (<a href="./references#CD008414-sec-0100" title="">Characteristics of included studies</a>), the clinical and endoscopic recurrence data of this study were not included in meta‐analyses. </p> <p><b>Primary outcome</b> </p> <p>Clinical relapse was reported in four studies, defined as clinical recurrence grading score ≥ 2 in <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> and <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>, as a CDAI &gt; 150 plus a 100‐point increase in CDAI from baseline in <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>, or CDAI ≥ 200 in <a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>.The effect of 5‐ASA compounds in comparison to azathioprine or 6‐mercaptopurine on clinical relapse was uncertain (<a href="./references#CD008414-fig-0016" title="">Analysis 4.1</a>.; <a href="./full#CD008414-tbl-0004">summary of findings Table 4</a>). At the end of 24 months of treatment, 61% (103/170) of mesalamine treated participants clinically relapsed compared to 67% (119/177) of azathioprine participants (RR 0.90, 95% CI 0.76 to 1.07, 347 participants, 4 studies, I² = 38%; low certainty evidence). </p> <p><b>Secondary outcomes</b> </p> <p><b>Endoscopic recurrence</b> </p> <p>Endoscopic recurrence defined as a Rugeerts score ≥ 2, was reported in one study and meta‐analysis was not performed (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). The efficacy of 5‐ASA in comparison to purine antimetabolites agents for preventing endoscopic recurrence was uncertain (<a href="./references#CD008414-fig-0017" title="">Analysis 4.2</a>; <a href="./full#CD008414-tbl-0004">summary of findings Table 4</a>). After 24 months, 83% (15/18) of 5‐ASA treated participants relapsed compared to 65% (11/17) in the purine analogues group (RR 1.29, 95% CI 0.86 to 1.94; very low certainty evidence). </p> <p><b>Radiologic relapse</b> </p> <p>Radiologic relapse defined as a radiographic recurrence grading score ≥ 2, was reported in one study and meta‐analysis was not performed (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). The effect of 5‐ASA drugs on the radiologic relapse rate compared to purine analogues was uncertain (<a href="./references#CD008414-fig-0018" title="">Analysis 4.3</a>). At 24 months, 83% (15/18) of 5‐ASA participants experienced radiologic relapse compared to 76% (13/17) of the purine antimetabolites group (RR 1.09, 95% CI 0.78 to 1.52; very low certainty evidence). </p> <p>Endoscopic and radiologic relapse rates were reported by <a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>. However, the results lacked sufficient detail to be included in the meta‐analysis. At 24 months (91 participants), the reported endoscopic and radiologic relapse rates were 48% (95% CI 30 to 70) and 46% (95 CI 29 to 66) in the mesalamine intervention group compared to 16% (95% CI 7 to 35) and 33% (95% CI 19 to 54) in the purine antimetabolites group respectively. </p> <p><b>Surgical relapse</b> </p> <p>Surgical relapse defined as the need for another surgery was reported by <a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>. The effect of 5‐ASA compared to purine analogues on surgical relapse was uncertain (<a href="./references#CD008414-fig-0019" title="">Analysis 4.4</a>). During the follow‐up period of two years, the proportion of participants with surgical relapse was 35% (26/71) in the 5‐ASA group compared to 29% (21/71) in the purine analogues group (RR 1.24, 95% CI 0.77 to 1.98). </p> <p><b>Adverse events, serious adverse events and withdrawal due to adverse events</b> </p> <p>Adverse events and withdrawal due to adverse were reported in five studies, while serious adverse events were reported in all studies except for <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>. The effect of 5‐ASA drugs on safety when compared to the purine analogues was uncertain, as the quality of evidence ranged from low to very low (<a href="./full#CD008414-tbl-0004">summary of findings Table 4</a>). During a follow‐up period of 52 weeks to 24 months, the proportion of 5‐ASA participants who experienced at least one adverse event (<a href="./references#CD008414-fig-0020" title="">Analysis 4.5</a>) was 52% (107/207) compared to 47% (102/218) of purine analogue participants (RR 1.11, 95% CI 0.97 to 1.27, 425 participants, 5 studies, I² = 0%; low certainty evidence). Reported adverse events include leukopenia, abdominal pain, nausea, nasopharyngitis, diarrhoea and headache. Four per cent (6/152) of patients treated with 5‐ASA experienced serious adverse events compared to 17% (27/159) of the purine antimetabolites group (RR 0.30, 95% CI 0.11 to 0.80, 311 participants, 3 studies, I² = 9%; very low certainty evidence). The types of serious adverse events were not well described in the studies but included postoperative bowel obstruction and acute pancreatitis. Eight per cent (17/207) of the 5‐ASA group withdrew due to an adverse event during 52 weeks to 24 months of follow‐up compared to 19% (42/218) of the purine analogues group (RR 0.48, 95% CI 0.28 to 0.83, 425 participants, 5 studies, I² = 0%; low certainty evidence). Adverse events leading to withdrawal included severe epigastric intolerance, increase in liver function test results, leukopenia, and acute pancreatitis. </p> <p><b>HRQoL</b> </p> <p>Two studies with treatment duration of 52 weeks and 24 months reported on HRQoL based on the IBDQ score (<a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). The effect of 5‐ASA agents compared to purine analogues on HRQoL was uncertain. <a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a> reported on the proportion of participants with an IBDQ score &gt; 170 which is regarded as a symptomatic remission score (IBDQ scores ranged from 32 to 224). At 24 months of follow‐up (<a href="./references#CD008414-fig-0023" title="">Analysis 4.8</a>), 17% (3/18) of 5‐ASA treated participants reported an IBDQ score &gt; 170 compared with 12% (2/17) in the azathioprine group (RR 1.42, 95% CI 0.27 to 7.46; very low certainty evidence). <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>, assessed HRQoL based on the mean change in IBDQ scores compared to baseline (<a href="./references#CD008414-fig-0024" title="">Analysis 4.9</a>). The mean difference in IBDQ score at 52 weeks compared to baseline among the 5‐ASA treated group was 5 (SD 27.4) compared to 9 (SD 17.7) in the purine analogue group (MD ‐4.00, CI ‐14.36 to 6.36; 78 participants). </p> </section> <section id="CD008414-sec-0079"> <h4 class="title">5‐ASAs vs anti‐TNF‐ɑ</h4> <p>One study (34 participants; start of intervention: 2 to 4 weeks after surgery) compared mesalamine (3 g/day) to adalimumab (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>). The effect of mesalamine in comparison to adalimumab on preventing postoperative clinical, endoscopic and radiologic recurrence was uncertain (<a href="./full#CD008414-tbl-0005">summary of findings Table 5</a>). </p> <p><b>Primary outcome</b> </p> <p>Clinical relapse was defined as clinical recurrence grading score ≥ 2 (<a href="./references#CD008414-fig-0016" title="">Analysis 4.1</a>). Over 24 months of follow‐up, 50% (9/18) of 5‐ASA participants had clinical relapse compared to 12% (2/16) in the anti TNF‐ɑ intervention (RR 4.00, 95% CI 1.01 to 15.84; very low certainty evidence). </p> <p><b>Secondary outcomes</b> </p> <p><b>Endoscopic and radiologic recurrence</b> </p> <p>Endoscopic recurrence was defined as Rutgeert's score ≥ 2 (<a href="./references#CD008414-fig-0026" title="">Analysis 5.2</a>), while radiologic relapse was defined as a radiographic recurrence score ≥2 (<a href="./references#CD008414-fig-0027" title="">Analysis 5.3</a>). The proportions of participants with endoscopic and radiologic recurrence within the mesalamine and adalimumab groups were equal. Namely, 83% (15/18) of mesalamine treated participants and 6% (1/16) of adalimumab participants had both endoscopic and radiologic recurrence after a follow‐up of 24 months (RR 13.33, 95% CI 1.98 to 89.95; very low certainty evidence for both outcomes). </p> <p><b>Adverse events, serious adverse events and withdrawal due to adverse events</b> </p> <p>The effect of oral 5‐ASA compounds compared to anti TNF‐ɑ on adverse events (<a href="./references#CD008414-fig-0028" title="">Analysis 5.4</a>), and withdrawal due to adverse events (<a href="./references#CD008414-fig-0029" title="">Analysis 5.5</a>), was uncertain (<a href="./full#CD008414-tbl-0005">summary of findings Table 5</a>). After 24 months, the proportion of participants who experienced adverse events in the 5‐ASA group was 78% (14/18) compared to the 69% (11/16) of the adalimumab group (RR 1.13, 95% CI 0.75 to 1.71; very low certainty evidence). Reported adverse events include bronchitis, nasopharyngitis, abdominal pain, arthralgia and exacerbation of Crohn's disease. Over 24 months of follow‐up, 0% (0/18) of 5‐ASA participants withdrew from the study due to adverse events compared to 6% (1/16) of adalimumab participants (RR 0.30, 95% CI 0.01 to 6.84; very low certainty evidence). Adverse events leading to withdrawal included atopic dermatitis and severe exacerbation of Crohn's disease. </p> <p><b>HRQoL</b> </p> <p>The effect of 5‐ASA compared to adalimumab on HRQoL was uncertain (<a href="./references#CD008414-fig-0030" title="">Analysis 5.6</a>; <a href="./full#CD008414-tbl-0005">summary of findings Table 5</a>). At 24 months, an IBDQ &gt; 170 was reported in 17% (3/18) of 5‐ASA participants compared to 88% (14/16) of adalimumab participants (RR 0.19, 95% CI 0.07 to 0.54; very low certainty evidence). </p> </section> <section id="CD008414-sec-0080"> <h4 class="title">Sulphasalazine versus placebo</h4> <p>There were two studies (298 participants; start of intervention: 0 to 4 weeks after surgery) that compared sulphasalazine (3 g/day) with placebo (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>; <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>). </p> <p><b>Primary outcome</b> </p> <p>Clinical relapse defined as 'proven radiological, endoscopic or operation findings' (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>), or as a scoring system developed for the study that considered symptoms, signs and impact (<a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>), was reported in both studies. The effect of sulphasalazine compared to placebo for maintaining surgically‐induced remission in Crohn's disease is uncertain due to low certainty evidence (<a href="./references#CD008414-fig-0031" title="">Analysis 6.1</a>; <a href="./full#CD008414-tbl-0006">summary of findings Table 6</a>). After 18 to 36 months of follow‐up, 66% (95/143) of sulphasalazine participants relapsed compared with 71% (110/155) of placebo participants (RR 0.88, 95% CI 0.56 to 1.38, I² = 38%; low certainty evidence). </p> <p><b>Secondary outcomes</b> </p> <p>The certainty of the evidence regarding adverse events of sulphasalazine is very low (<a href="./references#CD008414-fig-0032" title="">Analysis 6.2</a>, <a href="./full#CD008414-tbl-0006">summary of findings Table 6</a>). Adverse events were reported only in <a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> and meta‐analysis was not performed. After 18 months of follow‐up, one participant belonging to the placebo group (3%; 1/34) experienced nausea caused by a parallel consumption of acetylsalicylic acid and was withdrawn from the study, compared to none in the sulphasalazine group (0%; 0/32) (RR 0.35, 95% CI 0.01 to 8.38; very low certainty evidence). </p> <p>Endoscopic recurrence, radiological relapse, adverse events, serious adverse events and HRQoL were not reported on in either study. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008414-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008414-sec-0081">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008414-sec-0136">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008414-sec-0081"></div> <section id="CD008414-sec-0082"> <h3 class="title" id="CD008414-sec-0082">Summary of main results</h3> <p>This updated review includes 14 studies (1867 participants) investigating the use of 5‐ASA agents for maintenance of remission in Crohn's disease after surgery. Sulphasalazine agents, the earliest class of 5‐ASA drug, have not shown efficacy compared to placebo for preventing clinical relapse (low certainty evidence), although there were just two older studies for this comparison. Similarly for 5‐ASA versus no treatment, efficacy was not demonstrated, although again there was just a small number of participants in one study. Both of these results were judged to be of low certainty evidence due to quality issues and imprecision. </p> <p>5‐ASA agents when compared with placebo were efficacious for the prevention of clinical relapse and this result was rated as moderate certainty evidence on GRADE analysis, with five studies included in this analysis. The number needed to treat to prevent one relapse was 13. Endoscopic recurrence was not as consistently reported with only three studies included in the analysis. The effect of 5‐ASA on endoscopic recurrence is uncertain due to very low certainty evidence due to substantial heterogeneity and high risk of bias. </p> <p>5‐ASA agents compared to purine analogues were also investigated. There was no difference between 5‐ASA agents and purine analogues in preventing clinical relapse, although this outcome was reported as low certainty evidence due to risk of bias and imprecision. The secondary outcome of preventing endoscopic recurrence was also analysed and no difference in efficacy between the agents was found, however this outcome was rated as very low certainty evidence due to a high risk of bias and very serious imprecision. </p> <p>A single study compared two different dosing regimens of the same 5‐ASA agent (4 g/day versus 2.4 g/day), but found no difference in preventing clinical relapse.The certainty of evidence was reported as moderate due to imprecision from the small event numbers. </p> <p>One study compared 5‐ASA with an anti TNF‐ɑ agent (adalimumab) and found 5‐ASA to be inferior compared to adalimumab for prevention of clinical relapse. However, this outcome was rated as very low certainty evidence due to risk of bias and very serious imprecision. </p> <p>The effect of 5‐ASA on adverse events was uncertain. The overall certainty of the evidence for adverse event outcomes ranged from very low to low due to serious imprecision and high risk of bias. 5‐ASA did not appear to increase the risk of adverse events, serious adverse events or withdrawal due to adverse events when compared with placebo, no treatment or adalimumab. 5‐ASA participants had fewer serious adverse events and withdrawals due to adverse events than participants who received purine antimetabolites. </p> <p>5‐ASA preparations are ineffective for maintenance of medically‐induced remission in Crohn’s disease (<a href="./references#CD008414-bbs2-0027" title="AkobengAK , ZhangD , GordonM , MacDonaldJK . Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD003715.pub3] ">Akobeng 2016</a>). It is not clear why the evidence suggests a difference in efficacy for 5‐ASA agents in patients with medically‐ and surgically‐induced remission. One possibility could be that disease activity levels at study entry may not be comparable. The limitations of a CDAI score within clinical trials has previously been noted (<a href="https://archie.cochrane.org/sections/documents/view?version=48830176447641864705101203174505%26format=REVMAN#STD-Caprilli-1994" target="_blank">Caprilli 1994</a>), and most of the clinical trials performed to evaluate the role of 5‐ASA in the maintenance of medically‐induced remission defined remission using the CDAI score. As most of the trials involved in this review used surgical resection of macroscopically diseased bowel as inclusion criterion, it follows that many of these participants may have less active disease at study entry compared to participants in trials of medically‐induced remission. This may explain the observed difference in efficacy of 5‐ASA agents. </p> <p>It is also possible that the length of time in remission may partly explain this difference in efficacy. Many of the studies in the review of medically‐induced remission included patients who had been in remission for significant periods of time prior to study entry (<a href="./references#CD008414-bbs2-0027" title="AkobengAK , ZhangD , GordonM , MacDonaldJK . Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD003715.pub3] ">Akobeng 2016</a>). By contrast, most of the studies in this review required entry and initiation of therapy within 12 weeks of surgery. Evidence obtained from studies with a follow‐up of greater than 12 months still favoured the use of 5‐ASA agents, but as the longest study follow‐up was 36 months, it is possible that if a longer follow‐up was used this effect would not be sustained. </p> </section> <section id="CD008414-sec-0083"> <h3 class="title" id="CD008414-sec-0083">Overall completeness and applicability of evidence</h3> <p>With the increase of studies in this updated review, the overall volume and utility of the synthesised data has improved. This has facilitated meaningful comparisons. Moderate certainty evidence indicates that 5‐ASA is superior to placebo for maintaining surgically‐induced remission in Crohn's disease. The effect of 5‐ASA on endoscopic recurrence was uncertain as the certainty of the evidence was very low, so this would be an outcome of interest if further studies do occur in this context. </p> <p>The evidence is less complete when 5‐ASA agents are compared with the two key medication classes that are routinely considered in the post‐surgical setting (i.e. purine analogues and anti TNF‐ɑ agents). The evidence shows no difference in efficacy when 5‐ASA is compared with purine analogues. There was a difference in safety favouring 5‐ASA over purine analogues. As these results were rated as very low or low certainty predominantly due to issues with imprecision, this is an area that needs to be addressed. Similarly, there is just one trial with 34 patients comparing 5‐ASA with anti TNF‐ɑ agents and therefore further research is warranted. </p> <p>The longest follow‐up period was six years, with the majority of trials following participants for less than three years and again this further limits the applicability of the evidence to clinical practice. Time‐to‐event data would be useful as this would allow better insights on the efficacy of 5‐ASA for preventing relapse in post‐surgical Crohn's disease. </p> <p>The reporting of adverse events was a source of significant heterogeneity. The terminology used to describe adverse events in the included studies was not consistent. Terms used included minor adverse events, adverse events, side effects, major side effects, serious adverse events, serious events attributable to medication and withdrawals due to adverse events. Across studies, the reporting of adverse events was not consistent, with some studies reporting total event numbers, rather than the number of events per participants and some studies included treatment failure as an adverse event. There is now clear guidance on the reporting of adverse event outcomes in IBD trials and we strongly advise future studies to align with this. </p> </section> <section id="CD008414-sec-0084"> <h3 class="title" id="CD008414-sec-0084">Quality of the evidence</h3> <p>The included studies were inconsistent in terms of quality. The risk of bias was judged to be low in one study, unclear in seven studies and high in six studies. For the comparison of 5‐ASA to placebo, there was moderate certainty evidence of the efficacy of 5‐ASA for preventing clinical relapse in post‐surgical Crohn's disease. Whilst this has added to our confidence in the effect estimate, this is not the case for other comparisons and outcomes assessed in this review. In particular, the studies comparing 5‐ASA with purine analogues had issues with performance bias and sparse data. Additionally, there is just one trial comparing 5‐ASA with anti TNF‐ɑ agents. This led to other results being of very low or low certainty. Nonetheless, it is worth noting that there was little statistical heterogeneity noted across the comparisons. There was no indirectness as the included studies were all within the scope of the review. However, the limited number of studies precluded an assessment of publication bias. </p> </section> <section id="CD008414-sec-0085"> <h3 class="title" id="CD008414-sec-0085">Potential biases in the review process</h3> <p>We acknowledge that there are certain decisions which were made during the review process which may have introduced bias in the results. It was decided that sulphasalazine as a pharmacologically different 5‐ASA should be analysed separately, a decision that was not made for the previous version of the review. It is worth noting, however, that if 5‐ASA and sulphasalazine studies are combined, the results do not change. </p> <p>There were also significant problems classifying adverse events, as stated above. For the purposes of maintaining as homogenous reporting as possible, it was decided that we would not report on minor adverse events. Additionally, when considering the remaining adverse events, disease worsening or treatment failure were removed from the counting of adverse events. This was done for two reasons. Firstly, it was of concern that such patients may have already been included in the original relapse figures and be counted twice and whilst we tried to confirm this with authors, it was not always possible. Secondly, it was felt that such outcomes should be considered a natural result of treatments that do have a variable efficacy, it was not appropriate to consider these events as adverse events. However, it is possible such judgements may be a source of bias. </p> </section> <section id="CD008414-sec-0086"> <h3 class="title" id="CD008414-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>Since the original publication of this review (<a href="./references#CD008414-bbs2-0036" title="GordonM , NaidooK , ThomasAG , AkobengAK . Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD008414.pub2] ">Gordon 2011</a>), the UK National Institute for Health and Care Excellance guidance was updated to now consider 5‐ASA as a treatment in this context (<a href="./references#CD008414-bbs2-0046" title="National Institute for Health and Care Excellence. Crohn's disease: management (clinical guideline). nice.org.uk/guidance/cg152 (accessed 1 October 2012). ">NICE 2012</a>). However, the most recent NICE guidelines that were updated in May 2019 removed the recommendation stating that 5‐ASA had not been shown to be clinically or cost effective in terms of endoscopic relapse rates (<a href="./references#CD008414-bbs2-0047" title="National Institute for Health and Care Excellence. Crohn's disease: management (NICE guideline NG129). nice.org.uk/guidance/ng129 (accessed 3 May 2019). ">NICE 2019</a>). However, the NICE systematic review excluded studies with less than 12 months follow‐up and did not include abstracts. This led to several studies being excluded from the NICE guideline that have contributed to this review (<a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>; <a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>), and a reduction in the size of the evidence base. </p> <p>An additional concern is that the NICE systematic review used a network meta‐analysis methodology. However, several included studies that exerted influence on the network included non‐randomised active agents, specifically metronidazole. This does not meet the stringent requirement of transitivity for network meta‐analysis and therefore limits the conclusions that can be made from the NICE meta‐analysis. </p> <p>The most recent American Gastroenterological Association guideline does not recommend the use of 5‐ASA in this setting, citing the low GRADE rating on their committee analysis and so this review is not in agreement with this guideline (<a href="./references#CD008414-bbs2-0045" title="NguyenGC , LoftusEVJr , HiranoI , Falck‐YtterY , SinghS , SultanS , et al. American gastroenterological association institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology2017;152(1):271‐5. ">Nguyen 2017</a>). The European Crohn's and Colitis Organisation guidelines are older and include far fewer studies in their analysis, but conclude that while 5‐ASA is effective, it is less effective than purine analogues with no difference in safety (<a href="./references#CD008414-bbs2-0059" title="VanAsscheG , DignassA , ReinischW . The second European evidence‐based consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn's and Colitis2010;4:63‐101. ">Van Assche 2010</a>). This is also in contrast with the findings of this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008414-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD008414-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item of included study." data-id="CD008414-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item of included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008414-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 5‐ASA versus no treatment, Outcome 1 Clinical relapse at 12 months." data-id="CD008414-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 5‐ASA versus no treatment, Outcome 1 Clinical relapse at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 5‐ASA versus no treatment, Outcome 2 Adverse events at 12 months." data-id="CD008414-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 5‐ASA versus no treatment, Outcome 2 Adverse events at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 5‐ASA versus no treatment, Outcome 3 Withdrawals due to adverse events at 12 months." data-id="CD008414-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 5‐ASA versus no treatment, Outcome 3 Withdrawals due to adverse events at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5‐ASA versus placebo, Outcome 1 Clinical relapse at 48 weeks to 72 months." data-id="CD008414-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 5‐ASA versus placebo, Outcome 1 Clinical relapse at 48 weeks to 72 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5‐ASA versus placebo, Outcome 2 Endoscopic recurrence at 12 weeks to 72 months." data-id="CD008414-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 5‐ASA versus placebo, Outcome 2 Endoscopic recurrence at 12 weeks to 72 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5‐ASA versus placebo, Outcome 3 Adverse events at 12 weeks to 72 months." data-id="CD008414-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 5‐ASA versus placebo, Outcome 3 Adverse events at 12 weeks to 72 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5‐ASA versus placebo, Outcome 4 Serious adverse events at 48 weeks to 72 months." data-id="CD008414-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 5‐ASA versus placebo, Outcome 4 Serious adverse events at 48 weeks to 72 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5‐ASA versus placebo, Outcome 5 Withdrawal due to adverse events at 12 weeks to 72 months." data-id="CD008414-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 5‐ASA versus placebo, Outcome 5 Withdrawal due to adverse events at 12 weeks to 72 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High versus low dose 5‐ASA, Outcome 1 Clinical relapse at 12 months." data-id="CD008414-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 High versus low dose 5‐ASA, Outcome 1 Clinical relapse at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High versus low dose 5‐ASA, Outcome 2 Endoscopic recurrence at 12 months." data-id="CD008414-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 High versus low dose 5‐ASA, Outcome 2 Endoscopic recurrence at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High versus low dose 5‐ASA, Outcome 3 Adverse events at 12 months." data-id="CD008414-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 High versus low dose 5‐ASA, Outcome 3 Adverse events at 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High versus low dose 5‐ASA, Outcome 4 Adverse events leading to withdrawal at 12 months." data-id="CD008414-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 High versus low dose 5‐ASA, Outcome 4 Adverse events leading to withdrawal at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 1 Clinical relapse at 24 months." data-id="CD008414-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 1 Clinical relapse at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 2 Endoscopic recurrence at 24 months." data-id="CD008414-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 2 Endoscopic recurrence at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 3 Radiologic relapse at 24 months." data-id="CD008414-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 3 Radiologic relapse at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 4 Surgical relapse at 24 months." data-id="CD008414-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 4 Surgical relapse at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 5 Adverse events at 52 weeks to 24 months." data-id="CD008414-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 5 Adverse events at 52 weeks to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 6 Serious adverse events at 52 weeks to 24 months." data-id="CD008414-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 6 Serious adverse events at 52 weeks to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 7 Withdrawal due to adverse events at 52 weeks to 24 months." data-id="CD008414-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 7 Withdrawal due to adverse events at 52 weeks to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 8 HRQoL (IBDQ score &gt;170 at 24 months)." data-id="CD008414-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 8 HRQoL (IBDQ score &gt;170 at 24 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA versus purine antimetabolites, Outcome 9 HRQoL (mean IBDQ score change at 52 weeks)." data-id="CD008414-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA versus purine antimetabolites, Outcome 9 HRQoL (mean IBDQ score change at 52 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 1 Clinical relapse at 24 months." data-id="CD008414-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 1 Clinical relapse at 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 2 Endoscopic recurrence at 24 months." data-id="CD008414-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 2 Endoscopic recurrence at 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 3 Radiologic relapse at 24 months." data-id="CD008414-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 3 Radiologic relapse at 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 4 Adverse events at 24 months." data-id="CD008414-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 4 Adverse events at 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 5 Withdrawal due to adverse events at 24 months." data-id="CD008414-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 5 Withdrawal due to adverse events at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 6 HRQoL (IBDQ &gt;170)." data-id="CD008414-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 5‐ASA versus anti TNF‐ɑ, Outcome 6 HRQoL (IBDQ &gt;170).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sulphasalazine versus placebo, Outcome 1 Clinical relapse at 18 to 36 months." data-id="CD008414-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Sulphasalazine versus placebo, Outcome 1 Clinical relapse at 18 to 36 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008414-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/urn:x-wiley:14651858:media:CD008414:CD008414-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_t/tCD008414-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sulphasalazine versus placebo, Outcome 2 Withdrawal due to adverse events at 18 months." data-id="CD008414-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Sulphasalazine versus placebo, Outcome 2 Withdrawal due to adverse events at 18 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/media/CDSR/CD008414/image_n/nCD008414-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008414-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">5‐ASA compared to no treatment for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASA compared to no treatment for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> 5‐ASA (2.4 g/day)<br/> <b>Comparison:</b> no Treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>509 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>361 per 1,000<br/> (234 to 560) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.71<br/> (0.46 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110<br/> (1 Study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients in whom CDAI was &gt; 150, and who presented 100 points over their previous value, were considered to be relapsed (<a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.00<br/> (0.25 to 101.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 Study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to calculate absolute effects. Adverse events occurred in 4% (2/55) of participants in the 5‐ASA group compared to 0% (3/55) in the no treatment control group </p> <p>Reported adverse events included skin rash, epigastric pain, vomiting and nausea</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1,000<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 5.00<br/> (0.25 to 101.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> <p>( 1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We were unable to calculate absolute effects. Adverse events occurred in 4% (2/55) of participants in the 5‐ASA group compared to 0% (3/55) in the no treatment control group </p> <p>Withdrawals due to adverse events included skin rash, epigastric pain, vomiting and nausea </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of performance bias and unclear risk of selection of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (48 events) </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision (2 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">5‐ASA compared to no treatment for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008414-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">5‐ASAs compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASAs compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> 5‐ASA (3 to 4 g/day)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 48 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>360 per 1,000<br/> (312 to 416) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.72 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>730<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse defined as CDAI &gt;150 (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>; <a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a>); CDAI ≥ 250 (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>); clinical recurrence score &gt; 2 (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>); severe symptoms that warrant treatment plus radiological/endoscopic evidence (<a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up:12 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>726 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>603 per 1,000<br/> (407 to 901) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.56 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enodscopic recurrence defined as Rutgeerts score i ≥1 (<a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a>), Rutgeerts score i ≥ 2 (<a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a>), Rutgeerrts score i <i>&gt; 2</i> (<a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up:12 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1,000<br/> (53 to 170) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.60 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events included skin lesions, abdominal pain, diarrhea , vomiting and nausea </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up:48 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (14 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06<br/> (0.44 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>577<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported serious adverse events included postoperative bowel obstruction and pancreatitis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:12 weeks to 72 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1,000<br/> (49 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50<br/> (0.71 to 3.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included abdominal pain, pancreatitis and declining creatine clearance </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision (291 events)<br/> <sup>2</sup> Downgraded one level due to high risk of reporting bias and unclear risk of selection bias and outcome assessment<br/> <sup>3</sup> Downgraded two levels due to substantial heterogeneity ( I² = 84%)<br/> <sup>4</sup> Downgraded two levels due to very serious imprecision (43 events)<br/> <sup>5</sup> Downgraded two levels dur to due to very serious imprecision (18 events)<br/> <sup>6</sup> Downgraded two levels due to very serious imprecision (26 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">5‐ASAs compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008414-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High dose 5‐ASA compared to low dose 5‐ASA for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High compared to low dose 5‐ASAs for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention: high dose</b> 5‐ASAs (4.0 g/day)<br/> <b>Comparison: low dose</b> 5‐ASAs (2.4 g/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low dose 5‐ASA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with high dose 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1,000<br/> (98 to 291) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.38 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse reported as CDAI &gt; 150 or increase of 100 points from baseline (<a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>562 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1,000<br/> (337 to 584) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79<br/> (0.60 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic recurrence reported as Rutgeer's score &gt;1 (<a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up:12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000<br/> (3 to 138) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/> (0.15 to 7.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events include severe dyspepsia, increase in transaminases and limb cramps </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1,000<br/> (3 to 138) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04<br/> (0.15 to 7.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported adverse events include severe dyspepsia, increase in transaminases and limb cramps </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious imprecision (44 events) </p> <p><sup>2</sup> Downgraded one level due to due to serious imprecision (104 events) </p> <p><sup>3</sup> Downgraded two levels due to due to very serious imprecision (4 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High dose 5‐ASA compared to low dose 5‐ASA for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008414-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">5‐ASA compared to purine antimetabolites for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASA compared to purine antimetabolites for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> 5‐ASA (3‐4 g/day)<br/> <b>Comparison:</b> purine antimetabolites </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with purine antimetabolites</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up:24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>672 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1,000<br/> (511 to 719) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.76 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse defined as a clinical grading score ≥ 2 (<a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a>;<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) CDAI ≥ 200 (<a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>) </p> <p>CDAI &gt; 200 plus a 100‐point increase in CDAI from baseline (<a href="./references#CD008414-bbs2-0008" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More Information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up:24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>647 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>835 per 1,000<br/> (556 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (0.86 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic recurrence defined as Rugeerts score ≥ 2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up:24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>765 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>834 per 1,000<br/> (596 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.78 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiologic relapse defined as a radiographic grading score ≥ 2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up:52 weeks‐24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>468 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519 per 1,000<br/> (454 to 594) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11<br/> (0.97 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events included leukopenia, abdominal pain, nausea, nasopharyngitis, diarrhoea.and headache </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up:52 weeks to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1,000<br/> (19 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30<br/> (0.11 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>311<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported serious adverse events included postoperative bowel obstruction and pancreatitis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:52 weeks to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (54 to 160) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.48<br/> (0.28 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>425<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included severe epigastric intolerance, increase in liver function test results, leukopenia, acute pancreatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1118 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1,000</p> <p>(32 to 878)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.42</p> <p>(0.27 to 7.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝ <sup>1 8</sup><br/> VERY LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health related quality of life defined as IBDQ score &gt; 170</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to to high risk of performance bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (222 events) </p> <p><sup>3</sup> Downgraded two levels due to serious imprecision (26 events) </p> <p><sup>4</sup> Downgraded two levels due to serious imprecision (28 events) </p> <p><sup>5</sup> Downgraded one level due to serious imprecision (209 events) </p> <p><sup>6</sup> Downgraded two levels due to very serious imprecision (33 events) </p> <p><sup>7</sup> Downgraded one level due to serious imprecision (59 events) </p> <p><sup>8</sup> Downgraded two levels due to very serious imprecision (5 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">5‐ASA compared to purine antimetabolites for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008414-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">5‐ASAs compared to anti TNF‐ɑ for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASAs compared to anti TNF‐ɑ for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> 5‐ASAs (3 g/day)<br/> <b>Comparison:</b> anti TNF‐ɑ </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti TNF‐ɑ</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1,000<br/> (126 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.00<br/> (1.01 to 15.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse defined as a grading score ≥ 2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic recurrence</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000<br/> (124 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 13.33<br/> (1.98 to 89.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic recurrence defined as a Rutgeert's score ≥2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000<br/> (124 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 13.33<br/> (1.98 to 89.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiologic relapse defined as a score ≥2 (<a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1,000<br/> (516 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.13<br/> (0.75 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events included bronchitis, nasopharyngitis, abdominal pain, arthralgia and exacerbation of Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000<br/> (0 to 428) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.30<br/> (0.01 to 6.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events leading to withdrawal included atopic dermatitis and severe exacerbation of Crohn's disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>875 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>166 per 1,000</p> <p>(61 to 473)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.19</p> <p>(0.07 to 0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health related quality of life defined as (IBDQ &gt;170)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of performance bias and unclear risk of outcome assessment bias </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision (10 events) </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision (16 events) </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (25 events) </p> <p><sup>5</sup> Downgraded two levels due to very serious imprecision (1 event) </p> <p><sup>6</sup> Downgraded two levels due to very serious imprecision( 17 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">5‐ASAs compared to anti TNF‐ɑ for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008414-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sulphasalazine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sulphasalazine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> Sulphasalazine (3 g/day)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Sulphasalazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse</b><br/> Follow‐up:18 to 36 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>710 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1,000<br/> (397 to 979) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.88<br/> (0.56 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical relapse was proven by radiological, endoscopic, or operation findings (<a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a>) </p> <p>Clinical relapse was measured by a scoring system that considered symptoms, signs and impact (<a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1,000<br/> (0 to 246) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.35<br/> (0.01 to 8.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Adverse events leading to withdrawal included nausea</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health related quality of life (HRQL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for limitation due to high risk of reporting and detection bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (205 events) </p> <p><sup>3</sup> Downgraded one level due to unclear risk of bias for several domains </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (1 event) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sulphasalazine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008414-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summury of interventions and outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse</b> </p> <p><b>Events/</b> </p> <p><b>Serious</b> </p> <p><b>adverse events/ Withdrawal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2 mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 32<b>/</b>71 vs. 35/71 </p> <p><b>Surgical:</b> 25/71 vs. 18/71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 27/71 vs. 18/71 </p> <p><b>SAE:</b> 6/71 vs. 15/71 </p> <p><b>Withdrawal:</b> 6/71 vs. 15/71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo tablets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 13/44 vs. 14/43 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/44 vs. 3/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(2.4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse:</b> 20/55 vs. 28/55 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 2/55 vs. 2/55 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine</p> <p>(4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine</p> <p>(2.4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 17/101 vs. 27/101 </p> <p><b>Endoscopic &gt;1:</b> 45/101 vs. 59/105 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 2/101 vs. 2/105 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulfasalazine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse:</b> </p> <p>Total 0‐36 months: 89/111 vs. 99/121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Claversal (1000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> <p>(1000 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic:</b> 38/65 vs. 40/61 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 5/65 vs. 3/61 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐Mercaptopurine (50 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 32/47 vs. 33/44 vs.35/40 </p> <p><b>Endoscopic rate:</b> % (CI) </p> <p><b>Radiographic rate:</b> % (CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 9/47 vs. 6/44 vs. 4/40 </p> <p><b>SAE:</b> 2/47 vs. 0/44 vs. 0/40 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (4 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 47/154 vs. 59/170 </p> <p><b>Endoscopic:</b> 133/154 vs. 134/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SAE:</b> 8/154 vs. 9/170 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptomatic relapse:</b> 35/88 vs. 44/81 </p> <p><b>Endoscopic and radiologic rate:</b> significantly decreased in Group1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 7/88 vs. 10/81 </p> <p><b>SAE:</b> 1/88 vs. 0/81 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2.0 to 2.5 mg/kg/day) + Placebo mesalazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine (4 g/day) +</p> <p>Placebo azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean IBDQ change compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b> 34/37 vs. 32/41 </p> <p><b>SAE:</b> 0/37 vs. 10/41 </p> <p><b>Withdrawal:</b> 1/37 vs. 10/41 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab (160 mg at week 0, 80 mg at 2 weeks and 40 mg/week thereafter)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2 mg/kg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical by CDAI:</b> 1/16 vs.12/17 vs. 9/18 </p> <p><b>Endoscopic:</b> 1/16 vs. 11/17 vs. 15/18 </p> <p><b>Radiologic:</b> 1/16 vs. 13/17 vs. 15/18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ &gt;170:</p> <p>14/16 vs 2/17 vs 3/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b>11/16 vs. 14/17 vs. 14/18 </p> <p><b>Withdrawal:</b>1/16 vs. 1/17 vs. 0/18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 3/31 vs.8/35 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ score: significant decline in both groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suphasalazine (3 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 6/32 vs. 11/34 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal:</b> 0/32 vs. 1/34 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>AE = adverse events; CDAI = Crohn's disease activity index; ; g = gram; IBDQ = inflammatory bowel disease questionnaire; mg = milligram; N/A = not applicable; SAE = serious adverse events; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summury of interventions and outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008414-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Key study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from surgery till recruitment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Site of surgery % /</b> </p> <p><b>*exclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical relapse definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Endoscopic / histological recurrence definition/ other</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Sulfasalazine vs Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFZ 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0005" title="EweK , HerfarthC , MalchowH , JesdinskyHJ . Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicentre trial. Digestion1989;42(2):224‐32. EweK , HoltermullerKH , BaasU , EckardtV , KreigH , KutznerJ , et al. Prophylaxis after resection because of Crohn's disease by Salazosulfapyridin (Azulfidine). A double‐blind study [Rezidivprophylaxe nach Darmresektion wegen Morbus Crohn durch Salazosulfapyridin (Azulfidine). Eine Doppelblindstudie]. Verhandlungen der Deutschen Gesellschaft für Innere Medizin1977;82:930‐2. EweK , MalchowH , HerfarthC . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study‐‐initial results. Langenbeck's Archives of Surgery1984;364:427‐30. ">Ewe 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediately after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileocolon 92; Ileum 2; colon 6</p> <p>*non‐standard policy resection (radical or non‐radical)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proven by radiology, endoscopy or operation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFZ 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0014" title="WenckertA , KristensenM , EklundAE , BaranyF , JarnumS , WorningH , et al. The long‐term prophylactic effect of salazosulphapyridine (salazopyrin) in primarily resected patients with Crohn's disease. A controlled double‐blind trial. Scandinavian Journal of Gastroenterology1978;13(2):161‐7. ">Wenckert 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Special control charts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA vs no treatment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 2.4 g/day (24 mo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0003" title="CaprilliR , AndreoliA , CapursoL , CorraoG , D'albasioG , GioieniA ,   , et al. Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology &amp; Therapeutics1994;8(1):35‐43. CaprilliR , CorraoG , TaddeiG , TonelliF , TorchioP , ViscidoA . Prognostic factors for postoperative recurrence of Crohn's disease. Diseases of the Colon &amp; Rectum1996;39(3):335‐41. ">Caprilli 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>*disease localisation to the jejunum, proximal ileum, left colon or ano‐rectum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐asa vs placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day</p> <p>vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0002" title="BrignolaC , CottoneM , PeraA , ArdizzoneS , ScribanoM , DeFrancisR , et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology1995;108(2):345‐9. ">Brignola 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 56, ileocaecal 46</p> <p>*surgery other than in ileal or ileocaecal region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standardised form for description of endoscopic lesions by type and characteristics</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 1.5 g/day vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0006" title="FlorentC , CortotA , QuandaleP , SahmoundT , ModiglianiR , SarfatyE , et al. Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology &amp; Hepatology1996;8(3):229‐33. ">Florent 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 44 ; colonic 6; ileocolonic 48; Anoperineal lesion 12.</p> <p>* permanent stoma, small intestinal resection of more than 100 cm prior to the pretrial operation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before postoperative hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical recurrence grading &gt;2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i &gt; 2</p> <p><b>Radiographic relapse:</b> radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 4 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0009" title="LochsH , MayerM , FleigW , MortensenPB , BauerP , GenserD , et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology2000;118(2):264‐73. ">Lochs 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIeal 49; ileocolonic 56, colonic 5.</p> <p>* short bowel syndrome, presence of an ileocolonic stoma, more than 3 surgeries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 250 and CDAI &gt;200 but min 60 points increase for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 50, MES 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0010" title="McLeodRS , WolffBG , SteinhartAH , CarryerPW , O'RourkeK , AndrewsDF , et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology1995;109(2):404‐13. ">McLeod 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 8 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIeal 21; ileocolonic 46, colonic 33.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe symptoms to warrant treatment and radiological or endoscopic evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of endoscopic or radiological evidence of disease and included both asymptomatic and symptomatic patients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0013" title="SutherlandLR , MartinF , BaileyRJ , FedorakRN , PoleskiM , DallaireC , et al. A randomized, placebo‐controlled, double‐blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology1997;112(4):1069‐77. ">Sutherland 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 49, ileocolonic 50, unknown 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;150 as well as the absolute value of at least 60 points higher than baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p><b>HRQL: IBDQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA vs AZA or 6‐MP</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 mg/kg/day vs. AZA 2 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroG , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Max 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small bowel only 25.3; Colon 5.6; Small bowel and colon 9.8; upper gastrointestinal tract 16.2 </p> <p>*surgical procedures other than conservative surgery or for perianal disease only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p><b>Surgical relapse:</b> need for another surgical procedure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 3 g/day vs. 6‐MP 50 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0007" title="HanauerS , KorelitzB , RutgeertsP , PeppercornM , ThistedR , CohenR , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzBI , HanauerC , StephenB , Rutgeerts , PresentP , DanielH , et al. Postoperative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology1998;114:A1011. ">Hanauer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>before postoperative hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical recurrence grading &gt;2 (Hanauer et al)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiographic relapse:</b> radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MES 4g/day vs. AZA 2 mg/kg/day (52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0011" title="NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7(Suppl 1):S254. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>* Short bowel syndrome, an ileocolonic stoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt;200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>HRQL: IBDQ</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEZ 3 g/day vs. AZA 2 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51</p> <p>* fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 clinical recurrence grading scale ( Hanauer et al)</p> <p>2. CDAI &gt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiologic relapse</b> : ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQL:</b> IBDQ &gt; 170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA vs anti TNF‐α</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEZ 3 g/day vs. Adalimumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0012" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology2017;152(5):S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108:1731‐42. ">Savarino 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51</p> <p>* fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 on the clinical recurrence grading scale by Hanauer</p> <p>2. CDAI &gt;200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiologic relapse</b> : ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQL:</b> IBDQ &gt; 170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>5‐ASA VS 5‐ASA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 g/day MES vs. 2.4 g/day MES (12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008414-bbs2-0004" title="CaprilliR , CottoneM , TonelliF , SturnioloG , CastiglioneF , AnneseV , et al. Two mesalazine regimens in the prevention of the post‐operative recurrence of Crohns disease: a pragmatic, double‐blind randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2003;17(4):517‐23. ">Caprilli 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 64; Ileum/caecum/ascending colon 36</p> <p>* disease localization to jejunum, proximal ileum, transverse colon, left colon or anorectum </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 150 points or an increase in CDAI score of + 100 points from baseline.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 1</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>g = gram; mg = milligram; kg = kilogram; SFZ = sulphasalazine; MES = mesalamine; MEZ = mesalazine; 6‐MP = 6‐mercaptopurine; IBDQ = inflammatory bowel disease questionnaire; HRQL = health related quality of life; N/A = not applicable </p> <p>AZA = azathioprine; CDAI = Crohn's disease activity index</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Key study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/full#CD008414-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008414-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐ASA versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐ASA versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008414-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐ASA versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 48 weeks to 72 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Endoscopic recurrence at 12 weeks to 72 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.56, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events at 12 weeks to 72 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.60, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events at 48 weeks to 72 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.44, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to adverse events at 12 weeks to 72 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.71, 3.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐ASA versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008414-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High versus low dose 5‐ASA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Endoscopic recurrence at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events leading to withdrawal at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High versus low dose 5‐ASA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008414-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐ASA versus purine antimetabolites</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Endoscopic recurrence at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Radiologic relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Surgical relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events at 52 weeks to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.97, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events at 52 weeks to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.11, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawal due to adverse events at 52 weeks to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.28, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 HRQoL (IBDQ score &gt;170 at 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 HRQoL (mean IBDQ score change at 52 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐ASA versus purine antimetabolites</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008414-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">5‐ASA versus anti TNF‐ɑ</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Endoscopic recurrence at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Radiologic relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to adverse events at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 HRQoL (IBDQ &gt;170) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">5‐ASA versus anti TNF‐ɑ</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008414-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sulphasalazine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 18 to 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse events at 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sulphasalazine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008414.pub3/references#CD008414-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008414.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008414-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008414-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008414-note-0001">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD008414-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008414-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008414\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008414\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008414\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008414\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008414\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008414.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008414.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008414.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008414.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008414.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716912607"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008414.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716912613"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008414.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dab180e03f3f1',t:'MTc0MDcxNjkxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 